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ABSTRACT

All-atom molecular dynamics (MD) simulations combine the high temporal resolution of
experimental methods like smFRET and spatial resolution of methods like x-ray crystallography,
to provide a detailed dynamic picture of biomolecular processes. Here, microsecond-level
atomistic MD simulations have been used to characterize chemomechanical couplings in human
fibroblast growth factor 1 (hFGF1) and the spike proteins of SARS CoV-1 and SARS-CoV-2.
hFGF1 is a globular signaling protein that is involved in several physiological processes ranging
from cell proliferation to wound healing. Experimental studies have previously described the low
proteolytic and thermal stability of hFGF1, in addition to the stabilizing role of heparin. Here, a
conformational change in the hFGF1 heparin-binding pocket that occurs only when heparin is
absent, is described for the first time. Comparisons with experimental data indicate that this
conformational transition is implicated in the low thermal stability of hFGF1. Unique
electrostatic interactions that contribute to heparin-mediated stabilization are also described. This
work also describes a novel binding affinity estimation approach involving restrained umbrella
sampling simulations. The absolute binding affinity for the hFGF1-heparin interaction
determined using this approach is in very good agreement with data from isothermal titration
calorimetry (ITC) experiments. This binding affinity study revealed that restraining ligand
orientation is essential for effective sampling along a protein-ligand distance collective variable.
The differential dynamic behavior of the SARS-CoV-1 and CoV-2 spike proteins is also
described in this work. Spike protein activation is the first step in the “effective binding” process
leading to interaction with the human ACE2 receptor. This study shows that the active form of
the CoV-1 spike protein is less stable than that of the CoV-2 spike protein and that the energy

barriers associated with activation and inactivation are higher in CoV-2. A “pseudo-inactive”
state of the CoV-1 spike protein is described for the first time, wherein the N-terminal domain
(NTD) interacts with the receptor-binding domain (RBD). This highlights the potential role of
the NTD in spike protein inactivation. The relatively slower kinetics of spike protein activation
and inactivation in CoV-2 indicate that it might spend more time bound to the ACE2 receptor
than CoV-1, which in turn might provide an explanation for the higher transmissibility of CoV-2.
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INTRODUCTION

Due to advances in force field development, high-throughput modeling techniques and
supercomputing power, atomistic molecular dynamics (MD) simulation has become a standard
technique for investigating the behavior of proteins in explicit aqueous and membrane
environments. Experimental methods such as cryogenic electron microscopy (cryo-EM) and Xray crystallography essentially capture static images of specific conformational states which are
not necessarily functionally relevant1-3. The effectiveness of all-atom MD arises from the fact
that it is currently the only method capable of providing a dynamic picture of biomolecular
processes based on a combination of high spatio-temporal resolution and atomic-level detail3,4.
Most MD-based studies make the assumption that local conformational changes observed in
short, nanosecond-level simulations can be used to accurately describe functionally relevant
large-scale conformational transitions occurring on much longer timescales5,6. A recent study has
shown that longer simulations at the microsecond-level are the minimum requirement for an
accurate and effective characterization of both large-scale and local conformational transitions7.
This work focuses on the use of microsecond-level MD simulations to investigate the
conformational transitions associated with chemomechanical couplings in proteins, namely
human fibroblast growth factor 1 (hFGF1) and the spike proteins of SARS CoV-1 and SARSCoV-2. hFGF1 is a small globular signaling protein that is involved in numerous physiological
processes such as cell proliferation, wound healing, tumor growth and neurogenesis8,9. The
interaction of hFGF1 with heparin, its glycosaminoglycan (GAG) binding partner, is of particular
interest. While studies have shown that heparin binding does not cause any global
conformational transitions in hFGF1, it is thought to stabilize the protein and impart protection
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against proteolysis10-13. Microsecond-level unbiased MD simulations described in this work
reveal that the heparin-binding pocket of hFGF1 undergoes a conformational change when
heparin is absent. Based on comparisons with data from equilibrium unfolding experiments, it is
proposed that this conformational transition is implicated in the enhanced thermal instability14,15
displayed by unbound hFGF1. This study also describes the intermolecular and intramolecular
electrostatic interactions that contribute to the conformational dynamics of the hFGF1-heparin
complex.
Binding affinity calculations are an important aspect of any experimental or
computational study aiming to characterize protein-ligand interactions. Several computational
approaches have been developed to calculate binding affinities for biomolecular16-20. Extensive
sampling of ligand translational and rotational movements with respect to the protein, in addition
to ligand conformational dynamics, is a critical factor in the accurate quantification of the
entropic reduction caused by ligand binding21-23. A major disadvantage of popular methods like
Molecular Mechanics/Poisson-Boltzmann-Surface Area (MM-PBSA) is that they do not treat
entropic contributions to the binding free energy rigorously21,24. In addition, adequate sampling
of the overall conformational landscape of a system using traditional unrestrained MD
simulations is essentially impossible due to the timescales involved25,26. Computational
approaches that involve the calculation of a potential of mean force (PMF) along biased,
discretized reaction coordinates also tend towards inadequate sampling of factors like ligand
orientation16,27. Woo and Roux have developed an approach that revolves around the use welldefined geometrical restraints on the orientation and conformation of both protein and ligand16,27.
This method improves PMF convergence via a reduction in the conformational entropy of the
system16,27. In this work, a purely physics-based approach involving restrained umbrella
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sampling simulations, which is somewhat similar to the strategy devised by Woo and Roux16,27,
is described. The absolute binding affinity for the heparin-hGF1 interaction estimated via this
approach is in very good agreement with the binding affinity determined from isothermal
titration calorimetry (ITC) experiments.
As discussed in this work, hFGF1 undergoes a conformational transition and becomes
unstable in the absence of its binding partner (heparin hexasaccharide). In this case, the presence
of a binding partner is necessary to prevent a conformational change. At the other end of the
spectrum, the CoV-1 and CoV-2 spike proteins must undergo major conformational transitions
prior to interaction with the human ACE2 receptor. Several studies have shown that CoV-2 has a
higher transmissibility than the very similar CoV-128-34, but the mechanistic basis for this
differential transmissibility remains largely unexplored. The spike protein plays a critically
important role in the infection process of these two viruses, wherein the receptor-binding domain
(RBD) transitions from an inactive “down” position to an active “up” position prior to binding
the human ACE2 receptor28,33,35-41. Several studies have focused on the endpoint of this transition
(i.e. RBD-ACE2 binding) while mostly ignoring the mechanistic aspects that drive it. This work
investigates the potential contributions of this large-scale conformational transition to the
differential transmissibility and infectivity of CoV-1 and CoV-2. Extensive microsecond-level
unbiased MD simulations described in this work show that the active CoV-2 spike protein is
more stable than the active CoV-1 spike protein. In these simulations, the RBD of the active
CoV-1 spike protein spontaneously transitions to a “pseudo-inactive” state where it interacts with
the N-terminal domain (NTD). This conformation has not been observed in any cryo-EM or Xray crystallography studies thus far. Steered MD (SMD) simulations42 and nonequilibrium work
calculations43 have also been used to study conformational dynamics inaccessible to the shorter
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timescales of the unbiased simulations. These simulations strongly indicate that the energy
barriers for the confirmational transitions involved in activation or inactivation are lower for the
CoV-1 spike protein and that the CoV-2 spike protein undergoes conformational changes
relatively slowly. The slower kinetics of the CoV-2 spike protein provides an explanation for
why it might remain bound to ACE2 longer than the CoV-1 spike protein. This in turn might
potentially be connected to the higher transmissibility of CoV-2.
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Mechanistic Picture for Monomeric Human Fibroblast Growth Factor 1 Stabilization by
Heparin Binding
Vivek Govind Kumar1, Shilpi Agrawal1, Thallapuranam Krishnaswamy Suresh Kumar1, and
Mahmoud Moradi1
1

Department of Chemistry and Biochemistry, University of Arkansas, Fayetteville, AR 72701,
United States of America

ABSTRACT

Human fibroblast growth factor (FGF) 1 or hFGF1 is a member of the FGF family that is
involved in various vital processes such as cell proliferation, cell differentiation, angiogenesis
and wound healing. hFGF1, which is associated with low stability in vivo, is known to be
stabilized by binding heparin sulfate, a glycosaminoglycan that aids the protein in the activation
of its cell surface receptor. The poor thermal and proteolytic stability of hFGF1 and the
stabilizing role of heparin have long been observed experimentally; however, the mechanistic
details of these phenomena are not well understood. Here, we have used microsecond-level
equilibrium molecular dynamics (MD) simulations to quantitatively characterize the structural
dynamics of monomeric hFGF1 in the presence and absence of heparin hexasaccharide. We have
observed a conformational change in the heparin-binding pocket of hFGF1 that occurs only in
the absence of heparin. Several intramolecular interactions were also identified within the
heparin-binding pocket, that form only when hFGF1 interacts with heparin. The loss of both
intermolecular and intramolecular interactions in the absence of heparin plausibly leads to the
observed conformational change. This conformational transition results in increased flexibility of
the heparin-binding pocket and provides an explanation for the susceptibility of apo hFGF1 to
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proteolytic degradation and thermal instability. This study provides a glimpse into mechanistic
details of heparin-mediated stabilization of hFGF1 and encourages the use of microsecond-level
MD in studying the effect of binding on protein structure and dynamics. In addition, the
observed differential behavior of hFGF1 in the absence and presence of heparin provides an
example, where microsecond-level all-atom MD simulations are necessary to see functionally
relevant biomolecular phenomena that otherwise will not be observed on sub-microsecond
timescales.

INTRODUCTION
Thanks to the ever-increasing power of computers, improved force fields, and highthroughput modeling, all-atom MD is now routinely used to simulate proteins in simplified but
explicit aqueous/membrane environments. MD simulations combine the high spatial resolution
of experimental methods such as X-ray crystallography with the high temporal resolution of
experimental methods such as single-molecule FRET spectroscopy1,2. However, many MD
studies implicitly assume that local conformational transitions observed in short, nanosecondlevel simulations can be used to describe global protein conformational transitions that typically
occur on microsecond or millisecond time scales3,4. We have recently demonstrated that longer
microsecond-level simulations are essential for a more precise statistical characterization of both
local and global conformational transitions5. Here, we use microsecond-level unbiased MD
simulations to investigate the conformational and structural dynamics of monomeric hFGF16 and
the chemo-mechanical coupling between hFGF1 and heparin, its glycosaminoglycan (GAG)
binding partner.
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Fibroblast growth factors (FGFs) are signaling proteins that are involved in an extensive
variety of physiological processes7,8,9. The biological activity of FGFs is regulated through
interactions with linear anionic polysaccharides called glycosaminoglycans (GAGs), which
facilitate binding to specific receptors on the cell surface (FGFRs)10,11,12,13,14,15,16,17. Human
acidic fibroblast growth factor (hFGF1) is an important signaling molecule expressed in
embryonic and adult tissues for angiogenesis, cell proliferation and differentiation, tumor
growth, neurogenesis and wound healing10,18. Glycosaminoglycans (GAGs) consist of a class of
negatively charged and large linear polysaccharides formed of repeating disaccharide units in
which a uronic acid (either glucuronic acid or iduronic acid) moiety is combined with an amino
sugar (either N-acetyl-D-glucosamine or N-acetyl-D-galactosamine)19,20. Heparin is a GAG made
up of 2-O-sulfated iduronic acid and 6-O-sulfated, N-sulfated glucosamine (IdoA(2S)GlcNS(6S)), connected by α‐(1→4) glycosidic linkages21. The anionic nature of GAGs leads to
electrostatic interactions with positively charged (Lysine/Arginine-rich) regions of their target
proteins19,20. The hFGF1-heparin complex is the most broadly studied protein-GAG complex22,23.
The interaction of hFGF1 with specific heparin sulfate proteoglycans may be influenced
by the flexibility of the heparin-binding pocket24. In addition to the structural features of hFGF1,
GAG sulfation patterns also determine the functionality and specificity of protein-GAG
interactions25,26. hFGF1 is known to selectively recognize the GlcNS-IdoA2S-GlcNS sulfation
motif27. DiGabriele et al.28 crystallized a dimeric hFGF1-heparin sandwich complex (PDB entry:
2AXM) and showed that heparin binding does not result in any global conformational changes
within hFGF128,29. Solution nuclear magnetic resonance (NMR) and experimental binding
studies suggest that a monomeric hFGF1-heparin complex is also fully functional23,30. Apo
hFGF1 shows relatively low thermal stability and is known to be susceptible to thermal
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degradation31,32. Binding to heparin sulfate proteoglycans is thought to protect hFGF1 against
proteolytic degradation33,34.
Our microsecond-level all-atom equilibrium MD simulations reveal that a conformational
change occurs in the heparin-binding pocket of hFGF1 in the absence of heparin. We postulate
that this conformational change is responsible for the susceptibility of unbound hFGF1 to
thermal instability, as seen in equilibrium unfolding experiments. We have also studied the
intermolecular interactions of the hFGF1-heparin complex and the intramolecular interactions
that are unique to heparin-bound hFGF1 in order to obtain a clearer picture of the heparinmediated stabilization.

METHODS
Equilibrium unfolding of hFGF1 with heparin hexasaccharide

The temperature-based denaturation experiment was performed using the JASCO-1500
Circular dichroism spectrophotometer cohered with fluorescence detector. hFGF1 was diluted
with 10 mM phosphate buffer containing 100 mM NaCl at pH 7.2, to get a concentration of
33µM. The experiment was performed with and without heparin. For the measurements with
heparin, protein to heparin ratio of 1:10 was used. The fluorescence spectra were collected in 5
°C intervals from 25 °C to 90 °C. The fraction of denatured protein (Fd) at each temperature was
determined as Fd = (Y – YN)/(YD – YN); where, Y, YN, and YD are the fluorescence signals of the
305/350 nm fluorescence ratio at the native state (25 °C), each consecutive temperature, and the
denatured state (90 °C) respectively. The data set was fit using MS Excel. Tm, the temperature at
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which 50 % of the protein molecules exist in the denatured state(s), was calculated from the
fraction denatured protein population versus temperature graph.

All-atom equilibrium MD simulations
We have used all-atom equilibrium MD simulations to characterize the conformational
dynamics of hFGF1 with and without heparin hexasaccharide. Our simulations were based on the
x-ray crystal structures of the unbound hFGF1 monomer (PDB: 1RG8, resolution: 1.1
angstroms)6 and the dimeric complex with a heparin hexasaccharide (PDB:2AXM, resolution:
3.0 angstroms)28. We built three different models – monomeric apo hFGF1 from 1RG8;
monomeric heparin-bound hFGF1 (1RG8) using the heparin hexasaccharide from the dimeric
complex (2AXM) (Model 1) and monomeric heparin-bound hFGF1 from the dimeric complex
(2AXM) (Model 2). Residues 12-137 in the PDB files correspond to residues 26-151 in the
experimental sequence. The experiments were performed using a truncated version of hFGF1
(residues 13-154) which did not contain the unstructured 12 amino acid N-terminal segment.
The unstructured N-terminal segment is not known to be involved in receptor activation or
heparin binding. The heparin hexasaccharide consists of N, O6 disulfo-glucosamine and 2-Osulfo-alpha-L-idopyranuronic acid repeats28.
MD simulations were performed using the NAMD 2.1335 simulation package with the
CHARMM36 all-atom additive force field36. The input files for energy minimization and
production were generated using CHARMM-GUI37,38. For heparin-bound Model 1, the heparin
hexasaccharide segment from 2AXM was added to the 1RG8 structure using psfgen. The models
were then solvated in a box of TIP3P waters and 0.15 M NaCl. The heparin-bound systems had
approximately 23000 atoms while the apo system had 27,000 atoms.
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Initially, we energy-minimized each system for 10,000 steps using the conjugate gradient
algorithm39. Subsequently, we relaxed the systems using restrained MD simulations in a stepwise
manner (for a total of ∼1 ns) using the standard CHARMM-GUI protocol37. The initial
relaxation was performed in an NVT ensemble while all production runs were performed in an
NPT ensemble. Simulations were carried out using a 2-fs time step at 300 K using a Langevin
integrator with a damping coefficient of γ = 0.5 ps−1. The pressure was maintained at 1 atm using
the Nosé−Hoover Langevin piston method39,40. The smoothed cutoff distance for non- bonded
interactions was set to 10−12 Å and long-range electrostatic interactions were computed with the
particle mesh Ewald (PME) method41. The initial production run for each model lasted 15
nanoseconds, in which the conformations were collected every 2 ps. After each model was
equilibrated for 15 ns, the production runs were extended on the supercomputer Anton 2
(Pittsburgh Supercomputing Center) for 4.8 μs each, with a timestep of 2.5 fs. Conformations
were collected every 240 picoseconds.
VMD42 was used to analyze the simulation trajectories. The RMSD Trajectory tool42
was used to calculate the RMSD and Cα atoms were considered for these calculations. For
internal RMSD, the region of interest was aligned against its own initial configuration and
RMSD was calculated with respect to this configuration. RMSF of individual residues was
calculated using the Ca atoms by aligning the trajectory against the crystal structure. The
HBond42 and Salt Bridge42 plugins were used to generate the data for hydrogen bonding and saltbridge analysis respectively. For all interactions of interest, the number of frames with 1 or more
hydrogen bonds was counted to get the occupancy percentage. An occupancy cutoff of 50%, a
donor-acceptor distance cutoff of 4 Å and an angle cutoff of 35° were used to define hydrogen
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bond/salt bridge interactions. The salt bridge plugin42 was used to calculate the distance between
the two salt bridge residues over the course of the simulation, which is the distance between the
oxygen atom of the participating acidic residue and the nitrogen atom of the basic residue.
The Timeline plugin42 was used to analyze protein secondary structure. An internal measurement
method in VMD was used to count the number of water molecules within 3 Å of the heparinbinding pocket42.

RESULTS AND DISCUSSION
The putative role of heparin is to prevent the degradation of hFGF1. However, the specifics
of this heparin-mediated stabilization are still unclear. To address this issue, we have used
microsecond-level all-atom MD to compare and characterize the apo and heparin-bound forms of
hFGF1.
We have performed three unbiased all-atom MD simulations of monomeric hFGF1, each
for 4.8 μs. One apo and two heparin-bound models were simulated in the presence of explicit
water. The apo model and one of the heparin-bound models (Model 1) are based on the crystal
structure of monomeric apo hFGF1 (PDB entry: 1RG8)6. In order to examine the reproducibility
of our results, we have also made a second heparin-bound model of hFGF1. The second heparinbound model is extracted as a monomeric model from the crystal structure of dimeric heparinbound hFGF1 (PDB entry: 2AXM)28 (Supplemental Figure S1). Both heparin-bound models use
a heparin hexasaccharide. The heparin-bound models are quite similar and involve an hFGF1
monomer bound to heparin hexasaccharide. As the only difference between the apo and heparinbound models is the presence or absence of heparin, we can make meaningful comparisons
between all three sets of simulations (i.e., two holo and one apo models).
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Figure 1. Conformational change in the heparin-binding pocket of apo hFGF1. (A,B)
Cartoon representation of apo (red) and heparin-bound (blue) hFGF1 at the beginning and end
of the 4.8-µs simulations. The heparin-binding pocket (gold) moves away from the beta-trefoil
core of the apo protein. (C,D) RMSD time series for the apo (red) and heparin-bound (blue)
models of hFGF1 protein (C) and its heparin binding pocket (D). (E) RMSF estimations for
the apo (red) and heparin-bound (blue) models of hFGF1. (F) Thermal denaturation data for
hFGF1 in the absence (red) and presence (blue) of heparin. The presence of heparin causes the
Tm value to increase by around 20°C, indicating that heparin stabilizes the protein.
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A conformational change occurs in the heparin-binding pocket of the apo model

The most noticeable observation in our simulations is that the heparin-binding pocket
(residues 126-142) of the apo model becomes elongated and extends further outward and away
from the core beta-trefoil structure after approximately 2 μs (Figure 1A). This conformational
change is not observed in either of the two heparin-bound models (Figure 1B, Supplemental
Figure S2A). Comparing the internal root mean square deviation (RMSD) of the hFGF1
monomer from each system reveals that the presence of heparin hexasaccharide stabilizes the
protein and prevents this conformational change from occurring (Figure 1C, Supplemental
Figures S2A-B). All 3 models initially have internal RMSD values of approximately 1 Å from
their initial conformations, indicating little flexibility at least within the first 2 μs of simulations.
Both heparin-bound models settle down into a stable conformation within 0.5 μs (RMSD=1.5 to
2 Å approx.) (Figure 1C, Supplemental Figures S2A-B). On the other hand, the apo model
clearly undergoes a conformational change after 2 μs (RMSD=3 Å approx.) (Figure 1C, 1A).
This new conformation then remains stable for the remainder of the simulation (around 2.8 μs)
(Figure 1C, 1A).
A comparison of the internal RMSD of the heparin-binding pocket reveals that this
region plays a key role in the differential behavior of the apo (RMSD≈4 Å) and heparin-bound
models (RMSD≈0.5 Å) (Figure 1D, Supplemental Figures S2C-D). This indicates that the
absence of interactions with heparin leads to the decreased stability of the apo model. These
results are also supported by the root mean square fluctuation (RMSF) data for each model,
which was calculated for the Cα atoms of all protein residues (Figure 1E, Supplemental Figure
S2E-F). All three models show similar trends in the fluctuations for different regions, with the
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exception of the heparin-binding pocket. As expected, the heparin-binding pocket is much more
flexible in the apo model than in the heparin-bound models.
Thermal denaturation experiments were performed on monomeric hFGF1, in the absence
and presence of heparin hexasaccharide, to further validate our computational results. The Tm
value for the apo experimental model was approximately 42°C while the Tm value for the
heparin-bound experimental model was approximately 62.5°C (Figure 1F). The presence of
heparin thus increases the Tm value by around 20°C, indicating that heparin stabilizes the protein.
These observations are in qualitative agreement with the computational RMSD/RMSF data.

Figure 2. Cartoon representation of apo hFGF1. The positively charged residues of the
heparin-binding pocket (gold) are shown using stick representation. These residues are involved
in both intramolecular and intermolecular electrostatic interactions.
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Figure 3. Unique salt-bridge interactions facilitate the conformational change in the apo
model. (A) K132 (blue) of the heparin-binding pocket (gold) forms a salt-bridge with D84 of the
beta-trefoil core in the apo model (red). This interaction does not form in the heparin-bound
protein (blue). (B) Time series of the D84-K132 donor-acceptor salt bridge distances in the
presence (blue) and absence (red) of heparin. (C) K127 (blue) of the heparin-binding pocket
(gold) forms a weak salt-bridge with D46 of the beta-trefoil core in the apo model (red). This
interaction does not form in the heparin-bound Model 1 (blue). (D) Time series of the D46-K127
donor-acceptor salt bridge distances in the presence (blue) and absence (red) of heparin. (E)
Table of intramolecular interactions unique to the heparin-binding pocket of heparin-bound
hFGF1. (F) Time series of water molecule count within 3 Å of the heparin-binding pocket.
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Unique salt-bridge interactions facilitate the conformational change in the apo model

The conformational change that occurs in the apo model is localized in the heparinbinding pocket. Electrostatic interactions between positively charged residues in the heparinbinding pocket (Figure 2) and negatively charged residues in the beta-trefoil core help stabilize
the new conformation. We have identified two salt bridge interactions that are unique to the apo
model. They do not form in the two heparin-bound models (Figure 3A-D, Supplemental Figure
S3A-D). D84 of the beta-trefoil core interacts with K132 of the heparin-binding pocket (Figure
2, Figure 3A-B), while D46 of the beta-trefoil core interacts with K127 of the heparin-binding
pocket (Figure 2, Figure 3C-D). The destabilization of the heparin-binding pocket is
accompanied with the formation of a weak salt bridge between D46 and K127 (Figure 3C-D),
followed by the formation of a stronger salt bridge between D84 and K132 when the heparinbinding pocket becomes elongated and is extended outward (Figure 3A-B) and away from the
beta-trefoil core. Both K127 and K132 are known to interact with negatively charged heparin
residues30. Interactions with negatively charged residues of the beta-trefoil core possibly
compensate for the absence of interactions with heparin. Together, these salt bridges play a key
role in stabilizing the new conformation of the heparin-binding pocket for almost 2.8 μs.
Hydration analysis of the heparin-binding pocket (quantified by the number of water
molecules within 3 Å of this domain) provides additional evidence for a conformational change
within the heparin-binding pocket. Around 200 water molecules are present throughout both
heparin-bound trajectories (Figure 3F, Supplemental Figure S3E-F). During the apo simulation,
however, the count of water molecules increases to 280 after 2 μs (Figure 3F), thus coinciding
with the observed conformational change.
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K142

SGN5

K127

IDS6

Figure 4. Cartoon representation of the final frames of the two heparin-bound trajectories.
(A) Model 1 (blue) – heparin hexasaccharide from PDB entry 2AXM with monomeric hFGF1
from PDB entry 1RG8. (B) Model 2 (magenta) – one monomer and heparin hexasaccharide from
2AXM (dimeric). 6 residues in the heparin-binding pocket (R136, K132, K126, K127, R133,
K142) were found to interact with heparin hexasaccharide.
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Intramolecular interactions within the heparin-binding pocket help stabilize heparin-bound
hFGF1

Thus far, we have shown that monomeric hFGF1 is destabilized in the absence of
heparin and that a conformational change occurs within the heparin-binding pocket. This
conformational change does not occur in the heparin-bound models, which are considerably
more stable than the apo model. We have identified several unique intramolecular interactions
within the heparin-binding pocket that contribute to the increased stability of the heparin-bound
hFGF1 models (Figure 3E, Supplemental Figure S4). Hydrogen bond occupancies are quite
similar in both Model 1 and Model 2 (Figure 3E, Supplemental Figure S4). While these
interactions are also present briefly in the apo model, none of them meet the occupancy criteria
that would allow them to be described as hydrogen bonds (Figure 3E). We propose that these
intramolecular interactions within the protein may form as a consequence of intermolecular
interactions between positively charged residues of the heparin-binding pocket (Figure 2) and
negatively charged residues of heparin hexasaccharide. The strength of these intramolecular
interactions (occupancies between 54-97% in Model 1 and 64-94% in Model 2) might thus be a
factor that prevents the conformational change observed in the apo model from occurring in the
heparin-bound models. Among intramolecular hydrogen bonds observed in the apo model, only
one (L145-K142) involves the heparin-binding pocket (occupancy: 84%). All of the interactions
observed in the apo model—including salt bridges D46-R38 (90%), D53-R38 (87%), and E67K114 (60%)—also occur in the heparin-bound models with similar occupancies.
Secondary structure analysis reveals that parts of the heparin-binding pocket of the
apo model become unstructured and unravel into random coils when the conformational
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change occurs (Supplemental Figure S5A-B). This change in the secondary structure is then
maintained for the remaining 2.8 μs of the apo trajectory. This change in the secondary
structure is not observed in the heparin-bound models (Supplemental Figure S5C-D). The lack
of strong intramolecular interactions in the heparin-binding pocket of the apo model (Figure
3E) could thus account for the observed changes in the secondary structure.
Our findings are further validated by internal RMSD analysis of the heparin-binding
pocket of the apo (RMSD of ~4 Å) and heparin-bound (RMSD of ~0.5 Å) models (Figure 1D,
Supplemental Figures S2C-D). This analysis demonstrates that the heparin-binding pockets of
apo and heparin-bound hFGF1 have different internal conformations. Therefore, these
observations confirm the role of heparin-derived intramolecular interactions in maintaining
and promoting the structured nature of the heparin-binding pocket.

Characterization of intermolecular interactions that contribute to the stabilizing effects of
heparin
The heparin hexasaccharide in Model 1 fluctuates considerably before it eventually
undergoes a 180° rotation to settle down into a more stable conformation (Supplemental Figure
S6A). This transition occurs at the 1.25 μs mark and continues until the 2 μs mark (Supplemental
Figure S6A). On the other hand, the heparin molecule in Model 2 does not undergo any major
positional changes and attains a stable conformation very quickly (Supplemental Figure S6B).
As a result of the differences in behavior and position of the heparin hexasaccharide in each
model, slightly different intermolecular hydrogen bond interactions occur in each model in terms
of both occupancy as well as the residues involved (Figure 4, Table 1). Six residues in the
heparin-binding pocket (R136, K132, K126, K127, R133, K142) were found to be involved in
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these interactions (Figure 4A-B). With the exception of R133, intermolecular hydrogen bonds
involving these residues are present in the dimeric crystal structure (PDB entry: 2AXM)28. R133
was found to interact with heparin only in Model 1 (Figure 4A), while K142 was found to
interact with heparin only in Model 2 (Figure 4B). Intermolecular interactions involving N32,
N128 and Q141 are also present in the dimeric crystal structure28 but these residues only interact
briefly (hydrogen bond occupancies < 35%) with heparin in our simulation trajectories.
Occupancies are fairly similar for interactions involving R136 and K126 in both
models, while they are somewhat different for interactions involving residues K132 and K127.
R133 and K142 only interact with heparin hexasaccharide in Models 1 and 2, respectively. See
Table 1 and Fig. S7 for more details. As discussed previously, we have also identified six major
intramolecular interactions within the heparin-binding pocket that are unique to heparin-bound
hFGF1 (Figure 3E, Supplemental Figure S4). The presence of heparin ostensibly leads to the
formation of these intramolecular hydrogen bonds, which consequently contribute to the
stabilization of heparin-bound hFGF1. This is consistent with the thermal denaturation
experiments described above, where the Tm value increases by around 20°C upon heparin
binding (Fig. 1F), indicating an increase in the strength of protein intramolecular interactions
upon heparin binding.
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Table 1. Characterization of the hFGF1-heparin intermolecular interactions in the heparin
binding pocket. Table of intermolecular hydrogen-bonding interactions observed in the last
microsecond of both heparin-bound trajectories. R133 interacts with heparin only in Model 1,
while K142 interacts with heparin only in Model 2.

Acceptor
Donor

R136

K126

Model 1

Model 2

IDS4 (78%)

IDS2 (91%)

SGN5 (68%)

SGN3 (75%)

IDS4 (51%)

IDS4 (72%)
SGN3 (66%)

K132

SGN3 (53%)

IDS4 (52%)

SGN3 (54%)
K127

IDS2 (61%)
IDS6 (57%)

R133

K142

SGN5 (64%)

none

IDS4 (75%)

none
SGN5 (85%)
IDS6 (57%)

Conclusions

In this study, we used microsecond-level MD simulations to compare the behavior of
hFGF1 in the absence and presence of heparin hexasaccharide at the molecular level. These
simulations reveal a significant conformational difference within the heparin-binding pocket in
the absence and presence of the ligand. We conclude that the conformational change observed in
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the heparin-binding pocket of the hFGF1 model in the absence of the heparin is directly linked to
the thermal instability displayed by unbound monomeric hFGF1 experimentally. In addition to
the intermolecular interactions between hFGF1 and heparin hexasaccharide, we have identified
several intramolecular interactions within the heparin-binding pocket that are unique to the
heparin-bound models. Thermal denaturation experiments have revealed that the Tm value for
hFGF1 increases by approximately 20°C when bound to heparin. This suggests that the
intramolecular interactions play a key role in stabilizing monomeric hFGF1. Further
experimental and computational research is needed to elucidate the functional relevance of these
specific intramolecular interactions.

SUPPORTING INFORMATION

Supporting Figures S1-S7 provide the results of additional analyses. Cartoon representation of
dimeric hFGF1 with heparin; Stability of heparin-bound hFGF1 – RMSD/RMSF; Salt-bridge
analysis for heparin-bound models; Intramolecular interactions in the heparin-binding pocket
of heparin-bound Model 2; Secondary structure analysis related to conformational change in
apo model; Behavior of heparin in both heparin-bound models; Time series of hFGF1-heparin
interactions.
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ABSTRACT
The protein-ligand binding affinity quantifies the binding strength between a protein and its
ligand. Computer modeling and simulations can be used to estimate the binding affinity or
binding free energy using data- or physics-driven methods or a combination thereof. Here, we
discuss a purely physics-based sampling approach based on biased molecular dynamics (MD)
simulations, which in spirit is similar to the stratification strategy suggested previously by Woo
and Roux. The proposed methodology uses umbrella sampling (US) simulations with additional
restraints based on collective variables such as the orientation of the ligand. The novel extension
of this strategy presented here uses a simplified and more general scheme that can be easily
tailored for any system of interest. We estimate the binding affinity of human fibroblast growth
factor 1 (hFGF1) to heparin hexasaccharide based on the available crystal structure of the
complex as the initial model and four different variations of the proposed method to compare
against the experimentally determined binding affinity obtained from isothermal calorimetry
(ITC) experiments. Our results indicate that enhanced sampling methods that sample along the
ligand-protein distance without restraining other degrees of freedom do not perform as well as
those with additional restraint. In particular, restraining the orientation of the ligands plays a
crucial role in reaching a reasonable estimate for binding affinity. The general framework
presented here provides a flexible scheme for designing practical binding free energy estimation
methods.
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INTRODUCTION

Accurate quantification of absolute binding affinities remains a problem of major
importance in computational biophysics1,2,3,4. In principle, accurate binding free energy
calculations should be the cornerstone of any study investigating protein-ligand interactions.
However, the high computational costs that typically accompany such calculations necessitate
the improvement of the computational methods traditionally used to investigate complex
biomolecular interactions3,4,5. Experimentally determined binding affinities are commonly used
as benchmarks to judge the accuracy of various computational binding affinity estimation
methods5,6,7. Several experimental techniques can be used to study protein-ligand binding
equilibria5,8. For instance, isothermal titration calorimetry (ITC) can detect the interaction of
binding partners based on changes in solution heat capacity and binding partner
concentration8,9,10. Other methods such as fluorescence spectroscopy rely on changes in
fluorescence intensity upon ligand binding8,11,12. Surface plasmon resonance (SPR) can be used
to calculate binding affinities based on changes in refractive index that occur when an
immobilized binding partner interacts with a free binding partner8,13,14. Studies have found that
experimental binding affinities can vary depending on the experimental method used5,6,15.
Therefore, a thorough understanding of the experimental conditions used to generate reference
data is essential when comparing computationally determined binding affinities with
experimental values.
Several computational methods at varying levels of rigor and complexity have been
used to determine binding affinities for biomolecular interactions3,16-28. Knowledge-based
statistical potentials and force field scoring potentials are typically used to rank docked proteinligand or protein-protein complexes but can also be used for binding affinity prediction29,30,31.
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A major disadvantage of these methods is that they do not treat the entropic effects rigorously,
which effectively decreases the accuracy of such binding affinity predictions5,32. This is also the
case for methods like Molecular Mechanics/Poisson-Boltzmann-Surface Area (MM-PBSA) and
Molecular Mechanics/Generalized Born-Surface Area (MM-GBSA), which combine sampling of
conformations from explicit solvent molecular dynamics (MD) simulations with free energy
estimation based on implicit continuum solvent models33,34,35. Adequate sampling of both ligand
conformational dynamics as well as ligand roto-translational movements with respect to the
protein is essential for accurately quantifying the entropic reduction arising from the binding
event35,36,37. MM-PBSA/GBSA methods typically neglect the contribution of these entropic
terms to the binding free energy34,35.
One of the best-known binding free energy estimation methods is alchemical free
energy perturbation (FEP), where scaling of non-bonded interactions enables reversal decoupling
of the ligand from its environment in the bound state as well as the unbound state38,39,40,41. Most
entropic and enthalpic contributors to changes in binding affinity are typically considered during
FEP simulations, thus avoiding the approximations used by methods like MM-PBSA/GBSA5,42.
A disadvantage of FEP is the fact that ligands tend to move away from the binding site during
the decoupling process, which results in poorly defined target states of the FEP calculation being
used as starting states for the re-coupling process43. Using receptor-ligand restraints to resolve
this issue17,40,44,45 introduces some ambiguity to the way a standard state is defined, with a level
of correlation between the size of the simulation cell and the standard state46. This can be
corrected via the use of appropriate geometrical restraints16,47,23.
Unrestrained long timescale MD simulations should theoretically allow for the
investigation and accurate quantification of protein-ligand or protein-protein binding events48,49.
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While microsecond-level MD simulations provide a more accurate description of protein
conformational dynamics as compared to shorter simulations50, efficient sampling of the
conformational landscape remains a major issue and requires access to timescales beyond the
capabilities of current MD simulations51,52. Several methods have been developed to tackle the
sampling problem. Markov state models allow the sampling and characterization of native as
well as alternative binding states53,54,55. Similarly, weighted ensemble (WE) simulations sample
the conformational landscape along one or more discretized reaction coordinates based on the
assignment of a statistical weight to each simulation56,57. More traditionally, umbrella sampling
along such reaction coordinates can be used to guide the binding or unbinding of a ligand, after
which algorithms like the weighted histogram analysis method (WHAM) can be used to
calculate a unidimensional potential of mean force (PMF) which quantifies ligand binding and
unbinding along a reaction coordinate58,59. Better convergence of the calculated free energy
profiles can be achieved by the exchange of conformations between successive umbrellasampling windows as in the bias-exchange umbrella sampling (BEUS)60,61,62. Other methods
based on similar principles include umbrella integration63, well-tempered metadynamics64,
adaptive biasing force (ABF) simulations65 and variations of these techniques.
Incomplete sampling of important degrees of freedom, such as orientation of the ligand
with respect to the protein, remains a major disadvantage of unidimensional PMF-based
methods3,4. To resolve this problem, Woo and Roux3 have devised a method wherein explicitly
defined geometrical restraints on the orientation and conformation of the binding partners are
used to reduce the conformational entropy of the biomolecular system being studied3,4. This
results in improved convergence of the PMF calculation3,4. The introduction of a restraining
potential based on the root-mean-square deviation (RMSD) of the ligand relative to its average
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bound conformation, reduces the flexibility of the ligand and the number of conformations that
need to be sampled3,4. This method avoids the need to decouple the ligand from its surrounding
environment as required by alchemical FEP3,4,38-41. Recent studies have described applications
and extensions of the methodology proposed by Woo and Roux4,66.
Here, we describe a purely physics-based enhanced sampling method based on biased
MD simulations, which is similar in principle to the stratification strategy proposed by Woo and
Roux3,4. Although we use the US method as our enhanced sampling technique, the methodology
is generalizable to other techniques as long as they can be combined with additional restraints. A
major difference between our method and that of Woo and Roux3,4 is the use of the
unidimensional orientation angle of the ligand with respect to the protein as a collective variable
for restraining, as opposed to the use of three Euler angles. The formalism has also some other
major differences that are discussed in more detail below. We have used use this methodology to
calculate the binding affinity for the interaction of human fibroblast growth factor 1 (hFGF1)
with heparin hexasaccharide, its glycosaminoglycan (GAG) binding partner. hFGF1 is an
important signaling protein that is implicated in physiological processes such as cell proliferation
and differentiation, neurogenesis, wound healing, tumor growth and angiogenesis67,68,69,70,71.
GAGs are linear anionic polysaccharides that interact with positively charged regions of FGF
binding partners to regulate their biological activity70,72-80. The hFGF1-heparin complex is the
most well-known and broadly characterized protein-GAG complex81,82. Heparin binding is
thought to stabilize hFGF1 and impart protection against proteolytic degradation. In this study,
we show that the absolute binding affinity for the hFGF1-heparin interaction calculated using our
novel approach, is in good agreement with binding affinity data from ITC experiments.
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THEORETICAL FOUNDATION
Binding affinity is often quantified using the equilibrium dissociation constant (𝐾! ), defined as:
𝐾! = [𝑃][𝐿]/[𝑃: 𝐿]

(1)

where [𝑃], [𝐿], and [𝑃: 𝐿] are the concentrations of protein, ligand, and the protein-ligand
complex, respectively. Computationally, the absolute binding free energy (∆𝐺°), which is the
standard molar free energy of binding, is more convenient to calculate. The dissociation constant
and the absolute binding free energy are related via
∆𝐺° = 𝑅𝑇 ln

𝐾!
1𝑀

(2)

where 𝑅 is the gas constant and 𝑇 is the temperature. Various strategies have been used to
estimate ∆𝐺°, some of which were briefly discussed above. The methodology proposed here has
a significant resemblance to the stratification strategy of Woo and Roux3,4. However, the two
methods have major differences as will be discussed later.

Absolute binding free energy or ∆𝐺° is the free energy change associated with moving the ligand
from the bulk to the binding pocket. Within the formalism presented in this work, ∆𝐺° is
determined from the grid PMF 𝐺(𝒙), where 𝒙 is the position of the ligand mass center from the
center of the binding pocket, 𝐺(𝒙) is the potential of mean force (PMF) associated with the
ligand position 𝒙. In practice, we need to bin the 3D space and define the PMF at every bin or
grid point as:
𝐺(𝒙) = −𝑅𝑇 ln 𝑝(𝒙)

(3)

where 𝑝(𝒙) is the probability of finding the ligand at bin 𝒙.
We define Δ𝐺(𝒙) = 𝐺(𝒙) − 𝐺(𝟎), where 𝒙 = 𝟎 (i.e., the center of the binding pocket) is defined
as the grid point associated with the lowest grid PMF. One can show:
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∆𝐺° = −𝑅𝑇 ln

∫)*+,-. 𝑒
∫/01, 𝑒

"

"

#(𝒙)
'(

𝑑𝑉

#(𝒙)
'( 𝑑𝑉

= −𝑅𝑇 ln

∫)*+,-. 𝑒
∫/01, 𝑒

"

"

2#(𝒙)
'(

𝑑𝑉

(4)

2#(𝒙)
'( 𝑑𝑉

in which the pocket refers to all 𝒙 where the ligand is considered bound (i.e., the binding pocket)
and bulk refers to all 𝒙 where the ligand is not interacting with the protein. Since Δ𝐺(𝒙) is the
same everywhere in the bulk, we can simplify Relation (4) as follows:
𝑉3

∆𝐺° = −𝑅𝑇 ln
𝑒

"

2#(𝒙! )
'(

𝑉4

= −Δ𝐺(𝒙4 ) − 𝑅𝑇 ln

𝑉3
𝑉4

(5)

where 𝑉4 is the bulk volume per protein associated with the standard concentration (i.e., 1 𝑀),
𝒙4 is any grid point in the bulk, and 𝑉3 is the binding pocket volume defined as:
𝑉3 = D

𝑒"

2#(𝒙)
'(

𝑑𝑉

(6)

)*+,-.

Defining Δ𝐺5 as the contribution of the difference between the volume of the binding pocket and
the bulk to the binding free energy:
Δ𝐺5 = −𝑅𝑇 ln

𝑉3
𝑉4

(7)

Combining (5) and (7), we have:
∆𝐺° = −Δ𝐺(𝒙4 ) + Δ𝐺5

(8)

We can find the bulk volume (𝑉4 ) associated with the standard concentration for a single protein
approximately as:
1
mol
1
𝑁6
𝑉4 =
=
𝐿 ≈ 1661 Å8
1𝑀
𝑁6

(9)

where 𝑁6 is the Avogadro’s constant. We can now rewrite Δ𝐺5 as:
Δ𝐺5 = −𝑅𝑇 ln

𝑉3
𝑉3
𝑉4
= −𝑅𝑇 ln 8 + 𝑅𝑇 ln 8 = Δ𝐺3 − Δ𝐺4
𝑉4
Å
Å

(10)
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in which Δ𝐺4 is the bulk volume contribution and Δ𝐺3 is the binding pocket contribution:
⎧Δ𝐺4 = −𝑅𝑇 ln 𝑉4 ≈ −7.42𝑅𝑇
⎪
Å8
2#(𝒙) 𝑑𝑉
"
⎨ Δ𝐺3 = −𝑅𝑇 ln 𝑉3 = −𝑅𝑇 ln D
'(
𝑒
⎪
8
Å
Å8
)*+,-.
⎩

(11)

Determining both Δ𝐺(𝒙4 ) and Δ𝐺3 requires finding the grid PMF Δ𝐺(𝒙). Δ𝐺(𝒙4 ) is the PMF
difference between the binding pocket center and the bulk and Δ𝐺3 also requires an estimate for
Δ𝐺(𝒙) within the binding pocket. We therefore do not need to find Δ𝐺(𝒙) for all 𝒙 if we have a
good estimate for Δ𝐺(𝒙) within the binding pocket and in the bulk. Ideally, Δ𝐺(𝒙) for these
points can be determined by pulling the ligand out of the binding pocket towards the bulk and
using an enhanced sampling technique such as US to sample the space of a collective variable
such as 𝑑, i.e., the distance between the mass centers of the ligand and protein. Δ𝐺(𝒙) can be
estimated for all sampled grid points 𝒙 using this distance-based US simulation. Note that the
collective variable used for biasing would be 𝑑, while the collective variable used for the PMF
calculations would be the 3D position vector of the mass center of ligand with respect to
protein’s binding pocket center. One may estimate the grid PMF from the distance-based US
simulations using a non-parametric reweighting algorithm as discussed in the Methods section.
Δ𝐺(𝒙) can also be used to estimate Δ𝐺3 as defined in Relation (11). There is often no need to
strictly define the binding pocket since only low Δ𝐺(𝒙) values have nonnegligible contribution
to 𝑉3 and thus even if we include all sampled grid points, only those close to the binding pocket
center have nonnegligible contributions.
A practical issue with determining Δ𝐺(𝒙4 ) is the convergence. The key obstacles for the
sampling that slow down the convergence are the orientation of the ligand, and the
conformational changes of the ligand and protein. Using an approach similar in spirit to the
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previously proposed stratification strategy3,4,35, we can circumvent extensive sampling of these
degrees of freedom. Let us first focus on the orientation of the ligand (Ω). We can restrain Ω
9

during the distance-based US simulations using a biasing potential (: 𝑘Ω: ) and later correct the
free energy difference based on the PMF associated with the Ω, which is different in the bulk
(𝐹(𝒙; , Ω)) and in the binding pocket (𝐹(𝟎, Ω)). More generally, for any grid point 𝒙, we may
determine Δ𝐺(𝒙) based on the PMF associated with the Ω at 𝒙 (𝐹(𝒙, Ω)) and 𝟎 (𝐹(𝟎, Ω)):
2#(𝒙)
𝑒 " '(

<(𝒙,>)
'(

𝑑Ω

? "<(𝟎,>)
∫@ 𝑒 '(

𝑑Ω

?

=

"
∫@ 𝑒

(12)

Note that 𝐹(𝒙, Ω) is the PMF associated with 𝒙 and Ω, defined such that:
?

𝐺(𝒙) = 𝑐 − 𝑅𝑇 ln D 𝑒 "

<(𝒙,>)
'(

𝑑Ω

(13)

@

where 𝑐 is an arbitrary constant. We therefore have:
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'(
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∫@ 𝑒 '( 𝑑Ω
9
<(𝒙,>)B ,>"
:
? "
'(
𝑑Ω
∫@ 𝑒

×

? "
∫@ 𝑒

9
<(𝟎,>)B ,>"
:
'(

? "<(𝟎,>)
∫@ 𝑒 '(

𝑑Ω

×

𝑑Ω

9
<(𝒙,>)B ,>"
:
'(

𝑑Ω

9
<(𝟎,>)B ,>"
:
? "
'(
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𝑑Ω

? "
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(14)

We now define 𝐺> (𝒙) as the grid PMF of the restrained system (by Ω):
?

𝐺> (𝒙) = −𝑅𝑇 ln D 𝑒

"

9
<(𝒙,>)B ,>"
:
'(

𝑑Ω

(15)

@

We also define 𝑈> (𝒙) as the average biasing potential at grid point 𝒙:

𝑈> (𝒙) =

9 "
,>
":
−𝑅𝑇 ln 〈𝑒 '( 〉𝒙

= −𝑅𝑇 ln

? "
∫@ 𝑒

9
<(𝐱,>)B ,>"
:
'(

? "<(𝐱,>)
∫@ 𝑒 '(

𝑑Ω

(16)

𝑑Ω

Now we have from Relations (14), (15), and (16):
Δ𝐺(𝒙) = Δ𝐺> (𝒙) − Δ𝑈> (𝒙)

(17)
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where the free energy of grid point 𝒙 from the center 𝟎 (Δ𝐺(x)) is calculated based on its
equivalent free energy (Δ𝐺> (𝒙)) in a system biased by a harmonic restraint on Ω and a correction
term Δ𝑈> (𝒙). For 𝒙 = 𝒙4 :

Δ𝑈> (𝒙4 ) = −𝑅𝑇 ln

9 "
,D
:
〈𝑒 " '( 〉/01,

(18)

9 "
,D
":
〈𝑒 '( 〉)*+,-.

To determine the above ensemble averages, we need to determine the PMF along 𝛺 for the
bound and unbound ligand and calculate the ensemble averages analytically using Relation (16).
Δ𝐺> (𝒙4 ) can be determined from PMF calculations, where the distance between the protein and
ligand is varied and the orientation of the ligand is restrained (distance-based BEUS with
restrained orientation). We note that:
𝑒"

𝑉3 = D

)*+,-.

2#(𝒙)
'( 𝑑𝑉

=D

𝑒"

2## (𝒙)"2E# (𝒙)
'(
𝑑𝑉

)*+,-.

𝑒"

≈D

2## (𝒙)
'(

𝑑𝑉 (19)

)*+,-.

where we assume Δ𝑈> (𝒙) is negligible for 𝒙 within the binding pocket. In other words,
$

〈𝑒

""

%#"
&'

$

〉𝒙 ≈ 〈𝑒

""

%#"
&'

〉𝟎 for 𝒙 close to 𝟎.

In brief, if we choose to restrain the orientation, our absolute binding free energy estimate
includes the following terms (using Relations (8) and (17)):
∆𝐺° = −∆𝐺> (𝒙4 ) + ΔU> (𝒙4 ) + Δ𝐺5

(20)

𝐹(𝒙4 , Ω) can be calculated numerically from orientation angle distribution of a free ligand:
F(𝒙4 , Ω) = −𝑅𝑇 ln 𝑝(Ω), where 𝑝(Ω) is determined from the distribution of Euler angles
9

(𝑝(𝜙, 𝜃, 𝜓) = F?" sin 𝜃, where 0 ≤ 𝜙, 𝜓 ≤ 2𝜋 and 0 ≤ 𝜃 ≤ 𝜋) given that:
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cos

$

〈𝑒

""

%#"
&'

Ω
𝜙
𝜃
𝜓
𝜙
𝜃
𝜓
= cos cos cos + sin sin sin
2
2
2
2
2
2
2

(21)

〉/01, can then be calculated using numerically calculated 𝐹(𝒙4 , Ω) and 𝑘 as used in the

simulations using Relation (16). 𝐹(𝟎, Ω) can be determined approximately using orientation$

based US simulations of bound ligand. F(𝟎, Ω) can then be used to estimate 〈𝑒

""

%#"
&'

〉)*+,-. using

Relation (16).

The above strategy can be extended to other degrees of freedom for which unbiased sampling
may hinder the convergence. Most notably, the internal conformational changes of the ligand and
that of the protein may also play a crucial role in slowing down the convergence. In the
following, we show how one can restrain not only the orientation of the ligand but also the rootmean-square-deviation (RMSD) of the ligand (denoted here by 𝑟) in distance-based US
simulations (along 𝑑) to speed up convergence. In this case, the grid PMF difference Δ𝐺(𝒙) is
calculated based on Δ𝐺>,G (𝒙), the grid PMF of a system whose Ω and 𝑟 are both restrained:
2#(𝒙)
𝑒 " '(

#(𝒙,>,H)
'(

𝑑Ω 𝑑𝑟

I ? "#(𝟎,>,H)
∫@ ∫@ 𝑒 '(

𝑑Ω 𝑑𝑟

I

=

?

"
∫@ ∫@ 𝑒

(22)

Using a similar strategy as in Relation (14), we have:
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which results in:
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Here we have defined 𝐺>,H (𝒙) as:
I
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We also define 𝑈G (𝒙) similar to 𝑈> (𝒙) in Relation (15) except for using 𝑟 instead of Ω. 𝑈>G (𝒙) is
also defined similar to 𝑈> (𝒙) except for the additional restraint on 𝑟:

𝑈>G (𝒙) =
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Finally, we have:
Δ𝐺(𝒙) = Δ𝐺>,H (𝒙) − Δ𝑈H (𝒙) − Δ𝑈>G (𝒙)

(27)

In brief, if we choose to restrain both the orientation and RMSD, our absolute binding free
energy estimate includes the following terms:
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∆𝐺° = −Δ𝐺>,H (𝒙4 ) + ΔUH (𝒙4 ) + ΔU>H (𝒙4 ) + Δ𝐺5

(28)

Here we are using an approximation similar to that in Relation (19):
𝑉3 ≈ D

𝑒"

2##,* (𝒙)
'(
𝑑𝑉

(29)

)*+,-.

Using Relations (20) and (28), we can generalize the stratification strategy to include three
restraints on arbitrary collective variables 𝛼, 𝛽, and 𝛾:
N
J,N
∆𝐺° = −Δ𝐺M,J,N (𝒙4 ) + ΔUN (𝒙4 ) + ΔUJ (𝒙4 ) + ΔUM (𝒙4 ) + Δ𝐺5

(30)

where:
Δ𝐺5 ≈ −𝑅𝑇 ln D

)*+,-.

𝑒"

2#+,,,- (𝒙) 𝑑𝑉
'(
Å8

− Δ𝐺4

(31)

METHODS
Isothermal titration calorimetry of hFGF-1 with heparin hexasaccharide
Isothermal titration calorimetry (ITC) data was obtained using MicroCal iTC 200 (Malvern Inc.).
The change in heat during the biomolecular interaction was measured by titrating the heparin
(loaded in the syringe) to the hFGF1 solution in the calorimetric cell. Both the protein and the
heparin samples were made in the buffer containing 10 mM phosphate buffer with 100 mM NaCl
at pH 7.2 and were degassed prior to loading. The protein to heparin ratio was maintained at 1:10
with the protein concentration being 100 µM and the heparin concentration being 1mM. A total
of 30 injections were conducted with a constant temperature of 25 °C and stirring speed of 300
rpm. One set of sites binding model was used for the ITC binding curve85. The standard binding
free energy ΔG° was determined from dissociation constant via Relation (2) at 𝑇 = 25℃.
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All-atom MD simulations
Our simulations were based on the x-ray crystal structure of the dimeric complex with a heparin
hexasaccharide (PDB:2AXM, resolution: 3.0 angstroms)86. One of the hFGF1 protomers was
removed leaving one protein and one ligand in the model of the holo protein. The model for the
apo protein was based on the x-ray crystal structure of unbound monomeric hFGF1 (PDB:
1RG8, resolution: 1.1 angstroms)87. The simulations (residues 12-137 in the PDB file correspond
to residues 26-151 in the experimental sequence) and experiments were performed using a
truncated version of hFGF1 (residues 13-154) which did not contain the unstructured 12 amino
acid N-terminal segment. The heparin hexasaccharide consists of N, O6 disulfo-glucosamine
and 2-O-sulfo-alpha-L-idopyranuronic acid repeats86. The models were solvated in a box of
TIP3P waters and 0.15 M NaCl. MD simulations were performed using the NAMD 2.1388
simulation package with the CHARMM36m all-atom additive force field89 Initially, we energyminimized the systems for 10,000 steps using the conjugate gradient algorithm90. Subsequently,
we relaxed the systems using restrained MD simulations in a stepwise manner (for a total of ∼1
ns) using the standard CHARMM-GUI protocol91,92. The initial relaxations were performed in an
NVT ensemble while the production runs were performed in an NPT ensemble. Simulations
were carried out using a 2-fs time step at 300 K using a Langevin integrator with a damping
coefficient of γ = 0.5 ps−1. The pressure was maintained at 1 atm using the Nosé−Hoover
Langevin piston method90,93. The smoothed cutoff distance for non-bonded interactions was set
to 10−12 Å and long-range electrostatic interactions were computed with the particle mesh
Ewald (PME) method94. The initial runs lasted 15 nanoseconds, followed by the productions run
on the supercomputer Anton 2 (Pittsburgh Supercomputing Center) for 4.8 μs, with a timestep of
2.5 fs. These equilibrium simulations have previously been described in a related study95. We
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used these equilibrium simulations to construct the PMF in terms of the RMSD of the protein
(𝑟3 ) both for the apo95 and holo proteins (for bulk and binding pocket, respectively). We also
used the holo protein simulations95 to construct the PMF in terms of the RMSD of the ligand (𝑟O )
in the binding pocket.

MD simulations of free heparin hexasaccharide

The heparin hexasaccharide86 was simulated in a rectangular water box without the protein. The
system was set up as described previously. The final conformation after relaxation was then used
as the starting conformation for 10 production runs for 40 ns each. The total simulation time was
around 400 ns. We used these unbiased simulations instead of US simulations to construct the
PMF of free heparin in the bulk in terms of ligand RMSD (𝑟O ).

Steered Molecular Dynamics (SMD) simulations
The final conformation of the hFGF1-heparin equilibrium simulation95 was used to generate
starting conformations for the non-equilibrium pulling simulations. Two collective variables96
were used for SMD simulations97: (1) distance between the heavy-atom center of mass of heparin
and that of the protein (𝑑) and (2) the orientation angle of heparin with respect to the protein (Ω).
Two independent sets of simulations were performed. The distance-based SMD simulation was
run for 9.5 ns, while the orientation based SMD simulation was run for 8 ns. The distance-based
SMD simulation was used to pull the heparin away from the protein by approximately 30 Å
(10→40 Å) with a force constant of 100 kcal/(mol.Å: ). The orientation angle was also restrained
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in these simulations with a force constant of 0.5 kcal/(mol.𝑑𝑒𝑔𝑟𝑒𝑒 : ) to stay close to its initial
orientation in the bound state. The orientation-based SMD simulation was used to rotate the
bound heparin locally with respect to the protein (0°→73°) with a force constant of 100
kcal/(mol.𝑑𝑒𝑔𝑟𝑒𝑒 : ).

Bias Exchange Umbrella Sampling (BEUS) simulations
Bias exchange umbrella sampling62,98,99 (BEUS), which is a variation of the US simulation
method, was performed to estimate grid PMF. Four independent sets of distance (𝑑) based BEUS
simulations were performed, with no restraints, restraint on Ω, restraint on 𝑟O and 𝑟3 , and
restraints on Ω, 𝑟O , and 𝑟3 . Two sets of BEUS simulations were also performed using the Ω
collective variable, one with and one without a restraint on 𝑟O and 𝑟3 . Selected SMD
conformations were assigned to individual BEUS windows with equal spacing in each one of
these BEUS simulations. The distance-based BEUS simulation ran for 10 ns with 31
replicas/windows and the orientation-based simulation ran for 10 ns with 30 replicas/windows.
The force constant used for ligand-protein distance (𝑑) in distance-based BEUS was 2
kcal/(mol.Å: ) while the orientation was restrained as in SMD simulations using a force constant
of 0.5 kcal/(mol.𝑑𝑒𝑔𝑟𝑒𝑒 : ). For orientation-based BEUS simulations, the force constant for the
ligand orientation angle (as in SMD simulations) was set to 0.5 kcal/(mol.𝑑𝑒𝑔𝑟𝑒𝑒 : ). The force
constant used for 𝑟O and 𝑟3 was 1 kcal/(mol.Å: ).
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Free energy calculations using non-parametric reweighting
Once the BEUS simulations described above were converged, a non-parametric reweighting
method98,100, which is somewhat similar to the multi-state Bennett acceptance ratio method101,
was used to construct PMF. In this method98, each sampled configuration will be assigned a
weight, which can be used to construct the PMF in terms of a desired collective variable.
Suppose that a system is biased (for instance, within a BEUS scheme) using N different biasing
potentials 𝑈P (𝒓), where 𝑖 = 1, … , 𝑁, and 𝒓 represents all atomic coordinates. Typically, 𝑈P (𝒓) is
a harmonic potential defined in terms of a collective variable with varying centers for different 𝑖.
Assuming an equal number of sampled configurations from each of the 𝑁 generated trajectories,
we can combine them in a single set of samples {𝒓, } (irrespective of which bias was used to
generate each sample 𝒓, ) and determine the weight of each sample as:

𝑤, = 𝑐/ u 𝑒 "J(E.(𝒓%)"<. )
P

where 𝑐 is the normalization constant such that ∑, 𝑤, = 1 and both {𝑤, } and {𝐹P } are
determined iteratively using the above equation and the following:

𝑒 "J<. = u 𝑤, 𝑒 "JE.(𝒓%)
,

Converged 𝑤, values can be used to construct any ensemble averages including any PMF (e.g.,
𝐺(𝜻)) not only in terms of the collective variable used for biasing but also any other collective
variables that are sufficiently sampled. One may use a weighted histogram method to construct
the PMF as follows:
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𝐺(𝜻P ) = −𝑅𝑇 ln u 𝑤, 𝛿(𝜻(𝒓, ) − 𝜻P ),
,

𝛿(𝜻(𝒓, ) − 𝜻P ) = y

1, |𝜻(𝒓, ) − 𝜻P | < |𝜻(𝒓, ) − 𝜻R | 𝑓𝑜𝑟 𝑗 ≠ 𝑖
0, 𝑜𝑡ℎ𝑒𝑟𝑤𝑖𝑠𝑒

RESULTS AND DISCUSSION

We have calculated the absolute binding free energy for the interaction of hFGF1 with
heparin hexasaccharide using four variations of the stratification scheme described above, based
on a combination of SMD and BEUS simulations. The details of the methodology are discussed
in the Methods section. Four different methods are used with varying effectiveness in estimating
the absolute binding free energy. These methods include (1) the traditional distance-based BEUS
simulations that do not employ any additional restraining, (2) distance-based BEUS simulations
employing a restraint on the orientation of the ligand (Ω) defined based on the orientation
quaternion, (3) distance-based BEUS simulations employing a restraint on the RMSD of both
ligand and protein (rS , 𝑟3 ), (4) distance-based BEUS simulations employing a restraint on the
RMSD of both ligand and protein as well as the orientation of the ligand (Ω, rS , 𝑟3 ). In each case,
appropriate correction terms are calculated as discussed in the Theoretical Foundation section
above and shown in Table 1.
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Table 1: Summary of free energy calculation results.
No restraints

Ω restraint

𝑟/ , 𝑟0 restraint

Ω, 𝑟/ , 𝑟0 restraint

Grid PMF difference

Δ𝐺(𝒙1 ) =

Δ𝐺2 (𝒙1 ) =

Δ𝐺3! ,3# (𝒙1 ) =

Δ𝐺2,3!,3# (𝒙1 ) =

(kcal/mol)

−19.7 ± 1.1*

−13.2 ± 0.3

−17.7 ± 1.0

−17.0 ± 0.5

Orientation correction

N/A

Δ𝑈2 (𝒙1 ) =

N/A

(kcal/mol)
Ligand RMSD correction

4.4 ± 0.3
N/A

N/A

(kcal/mol)
Protein RMSD correction

N/A

N/A

(kcal/mol)

3 ,3#

Δ𝑈2!

(𝒙1 ) =

4.4 ± 0.3
Δ𝑈4$ (𝒙1 ) =

Δ𝑈4$ (𝒙1 ) =

0.5 ± 0.1

0.5 ± 0.1

3

3

Δ𝑈4%! (𝒙1 ) =

Δ𝑈4%! (𝒙1 ) =

0.8 ± 0.1

0.8 ± 0.1

Δ𝐺5 (kcal/mol)

3.7 ± 0.2

2.5 ± 0.2

2.3 ± 0.2

2.7 ± 0.2

Δ𝐺° (kcal/mol)

-16.0 ± 1.2

-6.3 ± 0.5

-14.1 ± 1.0

-8.5 ± 0.7

𝐾6 (𝜇𝑀)**

𝑂(1078 )

25

𝑂(1079 )

0.6

𝐾6 range (𝜇𝑀)***

107: − 1079

11 − 58

1078 − 107;

0.2 − 2.0

All error estimates are based on one standard deviation (s.d.). ** 𝐾! values are
determined directly from mean Δ𝐺° values using Relation (2). *** 𝐾! range is determined
from the lower and upper limits of Δ𝐺° values (mean ± s.d.) using Relation (2).
*

The most successful method is expected to be the one employing restraints on Ω, rS , 𝑟3 . The
largest contributor to the free energy is the difference between the grid PMF associated with the
heparin hexasaccharide at a grid point at the center of the binding pocket and at any grid point in
the bulk, which is -17.0 ± 0.5 kcal/mol (see Figure 1A and Table 1). We denote the PMF of the
ligand at a given position 𝒙 (with respect to the center of the heparin binding pocket) as the grid
PMF, since the PMF is estimated at different grid points in this approach.
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Figure 1. Computational (A-B) and experimental (C) heparin-hFGF1 binding free energy
measurements. (A) Average grid PMF in terms of |𝒙|,where 𝒙 is the 3D position vector of the
ligand with respect to the center of binding pocket determined from distance-based BEUS
simulations with Ω, 𝑟O , 𝑟3 restraints. The x axis represents |𝒙| and the y axis represents
Δ𝐺>,G< ,G= (|𝒙|), which is an average over all Δ𝐺>,G< ,G= (𝒙) with the same |𝒙|, i.e., the ligand
distance from the center of binding pocket. The error bar represents the standard deviation
obtained from all values of Δ𝐺>,G< ,G= (𝒙) at various grid points 𝒙 with the same |𝒙|. The dashed
line represents the value associated with Δ𝐺>,G< ,G= (|𝒙|) at |𝒙| = 30 Å. (B) The PMF associated
with the ligand orientation angle (Ω) for the bound heparin (i.e., 𝒙 ≈ 𝟎, ligand in the binding
pocket) and free heparin (i.e., 𝒙 ≈ 𝒙4 , ligand in the bulk). (C) Isothermogram representing the
titration of hFGF1 with heparin hexasaccharide. The inset is the experimentally estimated
dissociation constant and its associated binding free energy.
The PMF calculations above are based on the BEUS simulations along the protein-ligand
distance; however, the orientation and RMSD of the ligand and the RMSD of the protein are
restrained to speed up convergence. To account for the orientation bias, a correction term needs
to be applied, which is calculated from the PMF associated with the ligand orientation angle at
the bulk and binding pocket (Figure 1B). The orientation bias is estimated to be 4.4 ± 0.3
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kcal/mol (Table 1). Similarly, a correction term is calculated based on the PMF of the ligand
RMSD and that of the protein (Figure 2). These correction terms are estimated to be 0.5 ± 0.1
and 0.8 ± 0.1 kcal/mol, for the ligand and protein, respectively.
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Figure 2. PMF in terms of internal conformational fluctuations of the protein and ligand.
(A) PMF associated with the internal RMSD of heparin-bound (solid line) and apo (dashed line)
hFGF1, obtained from the equilibrium simulations. (D) PMF associated with the internal RMSD
of FGF1-bound (solid line) and free (dashed line) heparin hexasaccharide, obtained from
equilibrium simulations.
Finally, another term is needed to account for the difference in the volume accessible to the
ligand in the binding pocket and in the bulk (volume contribution). Figure 3 shows that Δ𝐺3 (or
𝑉3 ) for the distance-based BEUS simulations with no restraint as determined from 20 lowest free
energy grid points is almost equal to that obtained from all visited grid points inside or outside
the binding pocket. For the distance-based BEUS simulations with Ω, rS , 𝑟3 restraints, this term is
estimated to be 2.7 ± 0.2 kcal/mol, which results in an absolute binding free energy of -8.5 ± 0.7
kcal/mol. Based on our error analysis, Kd values calculated from the absolute binding free energy
were found to be in the micromolar range with an average value of 0.6 μM (using the mean Δ𝐺°
estimate) and ranging from 0.2 to 2.0 μM (based on the lower and upper bounds of free energy
estimates). These are in very good agreement with the Kd value obtained from ITC experiments
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that is 1.68 μM (Figure 1C). The free energy calculated from the experimental Kd (-7.91
kcal/mol) is also in good agreement with the computationally calculated binding free energy
(Figure 1C and Table 1).
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Figure 3. Estimating binding pocket volume (𝑉3 ) and its contribution to absolute binding
free energy (Δ𝐺3 ). (A) Grid PMF (Δ𝐺(𝒙)) associated with grid points with the 20 lowest PMF
values (black) along with estimated Δ𝐺3 based on the first 20 grid points (shown in an
accumulative manner in magenta). The distance-based BEUS simulations with no restraints are
used for these calculations. Dashed line shows the estimated Δ𝐺3 based on all visited grid points
inside or outside the binding pocket. The x axis shows the position vector of these 20 grid points.
(B) Binding pocket volume (𝑉3 ) calculated from 20 lowest grid PMF values (similar to A).
Dashed line shows the 𝑉3 estimated from all visited grid points inside or outside the binding
pocket. See the Methods section for more details.
The quantitative agreement between the computational and experimental binding affinity
estimates is a great indicator of the accuracy of our absolute binding free energy calculation
method. However, if proper restraining is not used as in the distance-based BEUS simulations
with no restraints or only RMSD restraints, the binding affinity estimates would be off by several
orders of magnitude. The simulations that only restrain the orientation of the ligand are
interestingly quite successful as well, being off only by one order of magnitude in terms of
binding affinity, which is generally considered a good estimate. This provides some evidence
that the orientation of the ligand is perhaps the degree of freedom with the most significant
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contribution to the absolute binding free energy besides the ligand-protein distance. We note that
the average grid PMF profiles along the ligand-protein distance for the four different methods
used here (as shown in Figure 4), confirm the differential behavior of these methods; however, it
is important to note that the correction terms should ideally eliminate these differences. This is
seen to some extent when comparing the two methods involving orientation restraints that
happen to estimate binding affinities that are reasonably close to the experimentally determined
value.

Recent computational studies have used the MM-GBSA method to calculate the binding free
energy of the hFGF1-heparin interaction, with values ranging from -84.9 kcal/mol to -106.1
kcal/mol102. The results obtained from the MM-GBSA approach are very different from our own
results, which is to be expected given that MM-GBSA ignores various contributors to the free
energy33,34,35. Studies have shown that the binding affinity and free energy results derived from
computational methods can be compared to experimental binding affinities obtained from ITC
experiments9,10. However, for a reliable computational free energy estimate, employing purely
physics-based free energy calculation methods such as those employed here has proven to be
difficult. Here we showed that using a careful strategy that considers all relevant free energy
terms and ensures the use of powerful enhanced sampling techniques, could result in good
quantitative agreements between the computational and experimental binding affinity estimates.
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Figure 4. Average grid PMF based on four alternative distance-based BEUS simulations.
Average grid PMF in terms of |𝒙|,where 𝒙 is the 3D position vector of the ligand with respect to
the center of binding pocket. The x axis represents |𝒙| and the y axis represents Δ𝐹(|𝒙|), which
is an average over all Δ𝐹(𝒙) with the same |𝒙|, i.e., the ligand distance from the center of
binding pocket. The error bar represents the standard deviation obtained from all values of
Δ𝐹(𝒙) at various grid points 𝒙 with the same |𝒙|. The dashed line represents the value associated
with Δ𝐹(|𝒙|) at |𝒙| = 30 Å. The inset summarizes different free energy terms involved in the
calculation of the absolute binding free energy and the dissociation constant.
The formalism presented in this work has significant similarities to the method previously
proposed by Woo and Roux3, and later implemented4,66. However, there are major differences
that make the current method more practical. The grid PMF and its various estimates provide a
simple conceptual framework to understand how restraining can be accounted for with
appropriate correction terms. The average grid PMF in terms of the ligand-protein distance
provides an alternative to the PMF in terms of 𝑑 as is often constructed. Relation (30) is a
general scheme that can be easily adapted to any number of restraints. The orientation angle of
the ligand with respect to the protein as determined using the orientation quaternion formalism,
provides a simple way of determining the absolute binding free energy with a feasible
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computational cost. Among the four different sets of restraints, the two involving orientation
restraints predict binding free energies similar to that determined experimentally.
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ABSTRACT
Within the last two decades, severe acute respiratory syndrome (SARS) coronaviruses 1 and 2
(SARS- CoV-1 and SARS-CoV-2) have caused two major outbreaks. For reasons yet to be fully
understood the COVID-19 outbreak caused by SARS-CoV-2 has been significantly more
widespread than the 2003 SARS epidemic caused by SARS-CoV-1, despite striking similarities
between the two viruses. The spike protein, which binds to the host cell angiotensin converting
enzyme 2 (ACE2) in both SARS-CoV-1 and 2, has been implied to be a potential source of their
differential transmissibility. However, the mechanistic details of prefusion spike protein binding
to ACE2 remain elusive at the molecular level. Here, we have used an extensive set of
equilibrium and nonequilibrium microsecond-level all-atom molecular dynamics (MD)
simulations of SARS-CoV-1 and 2 prefusion spike proteins to determine their differential
dynamic behavior. Our results indicate that the active form of the SARS-CoV-2 spike protein is
more stable than that of SARS-CoV-1 and the energy barrier associated with the activation is
higher in SARS-CoV-2. Our results suggest that not only the receptor binding domain (RBD) but
also other domains such as the N-terminal domain (NTD), could play a crucial role in the
differential binding behavior of SARS-CoV-1 and 2 spike proteins.
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INTRODUCTION
Within the last two decades, SARS CoV-1 [1–3] and 2 [4–8] (CoV-1 and CoV-2,
respectively) have caused SARS epidemic and coronavirus disease 2019 (COVID-19) pandemic,
respectively. Various studies have shown that CoV-2 is more easily transmissible between
humans in comparison to CoV-1 [9–12]. However, given the striking similarity of the two
viruses, the molecular-level explanation of their differential transmissibility is largely missing.
The two viruses share several highly conserved structural and functional features [4, 13, 14]. The
spike protein plays a crucial role in the infection process [13, 15–17] and has been the primary
target of various candidate drugs and vaccines [18–26].
CoV-1 and CoV-2 spike proteins have a high sequence identity of approximately 79% [4]
and the RBDs of both proteins interact with the human ACE2 receptor [9, 16, 17, 27–31].
Studies have shown that several regions of the CoV-2 spike protein are susceptible to mutations,
with the RBD being particularly vulnerable in this regard [32–35]. It is possible that therapeutic
agents targeting only the RBD-ACE2 interaction might eventually be rendered ineffective due to
the appearance of emerging variants. Therefore, diversifying the hot spots of the protein being
targeted by therapeutics and vaccines is essential in increasing their long-term efficacy. The
current study provides a rational framework for such directions by systematically studying the
differential behavior of the CoV-1 and CoV-2 spike proteins, highlighting significant regions of
the protein that are involved in the activation process, i.e., a large-scale conformational change in
the prefusion spike protein, which occurs prior to ACE2 binding.
Recently, several cryogenic electron microscopy (cryo-EM) and computational studies
have shed light on the differential receptor binding behavior of the CoV-1 and CoV-2 spike
proteins [9, 17, 27, 36, 37]. The RBD of the spike protein undergoes a large-scale conformational
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transition from an inactive “down” position to an active “up” position in order to access the
ACE2 receptors on the host-cell surface [9, 17, 27, 38–40]. Experimental studies investigating
the binding affinity of the spike protein RBD for the ACE2-peptidase domain (PD) have
produced varying results. Using surface plasmon resonance (SPR) and flow cytometry
techniques, respectively, Wrapp et al. [27] and Tai et. al. [17] have reported that the CoV-2 RBD
has a higher binding affinity for ACE2-PD than the CoV-1 RBD. For instance, the SPR-based
assay shows that the dissociation constant of the CoV-2 spike protein (Kd ≈ 14.7 nM) is 10-20
times lower than that of the CoV- 1 spike protein [27, 41]. In a different study, biolayer
interferometry has shown that the CoV-2 dissociation constant (Kd ≈ 1.2 nM) is only 4 times
lower than that of CoV-1, indicating that the binding affinities are generally comparable [9].
Such quantitative inconsistencies emphasize the need to improve our understanding of the
mechanistic aspects of the RBD-ACE2 interaction. A disadvantage of experimental techniques
like SPR and biolayer interferometry is that they require the protein to be immobilized prior to
measuring the binding affinity [42, 43]. This introduces a level of bias into these experimental
assays, particularly if the binding behavior of a protein is conformation-dependent, as is the case
for the coronavirus spike proteins. One may argue that some studies have neglected the fact that
the binding process involves not only the RBD- ACE2 interaction but also the spike protein
activation, a large-scale conformational change with a potentially significant contribution to the
differential binding behavior of SARS-CoV-1 and 2. Therefore, to gain a clearer understanding
of the enhanced infectivity of SARS-CoV-2, “effective binding” involving both the RBD-ACE2
interaction and the spike protein activation/inactivation process needs to be investigated. Here,
we focus on the latter, which has received less attention in the literature.
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Cryo-EM studies have successfully resolved structures of both spike proteins in the
inactive state, active unbound state, and active ACE2-bound state [9, 27, 31, 38, 44]. However,
cryo-EM and X-ray crystallography studies essentially capture static pictures of specific protein
conformations [45–47]. In addition, given the substantial differences in the experimental and
physiological conditions, it is not clear whether all relevant conformational states are captured
using these techniques. For instance, a recent single-molecule fluorescence resonance energy
transfer (smFRET) study has captured an alternative inactive conformation for the CoV-2 spike
protein [48] that is not consistent with those obtained from cryo-EM. It is thus important to
investigate the differential conformational landscapes of the CoV-1 and CoV-2 spike proteins in
terms of both important functional states and their dynamics. For this purpose, we use an
extensive set of microsecond-level unbiased and biased MD simulations. Here, we make certain
assumptions to be able to make progress towards deciphering the differential behavior of the two
spike proteins, such as relying on cryo-EM structures as our initial models, excluding the
unresolved transmembrane domain of the spike protein, and excluding the glycan chains in the
simulations. However, we treat the spike proteins of both viruses similarly so that a reliable
comparison can be made.
Allowing for the fact that this study has certain limitations as discussed previously, our
extensive all-atom equilibrium MD simulations show that the active CoV-2 spike protein is
potentially more stable than the active CoV-1 spike protein. We also report that the RBD of the
active CoV-1 spike protein can undergo a spontaneous conformational transition to a pseudoinactive state characterized by the interaction of the NTD and RBD, a state not observed in any
of the previous experimentally reported structures of CoV-1 or CoV-2 spike protein. This
observation is broadly in line with the recent smFRET experimental results indicating the
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presence of alternative inactive spike protein conformations [48]. More specifically, electrostatic
interaction analyses reveal that unique salt-bridge interactions between the NTD and RBD of the
CoV-1 spike protein, are involved in the major conformational transition observed in our
simulations. No large-scale conformational changes occur in any of the active CoV-2 spike
protein simulations or any of the inactive CoV-1 or CoV-2 spike protein simulations within the
timescale of our unbiased MD simulations (5 µs).
In order to investigate the longer timescale conformational dynamics inaccessible to
unbiased simulations [49], we have also employed extensive steered MD (SMD) simulations
[50] along with nonequilibrium work calculations [51] to make a semi-quantitative comparison
between the two proteins [52, 53]. The SMD simulations shed light on the energetics of the
conformational change associated with the activation and inactivation processes. The results
obtained from these enhanced simulations strongly suggest that the energy barriers for such
conformational transitions are significantly lower for the CoV-1 spike protein and that
conformational changes occur more slowly for the CoV-2 spike protein. This provides an
explanation for the conformational plasticity displayed by the active CoV-1 spike protein in our
simulations as well as the relative conformational stability of the active CoV-2 spike protein. The
results from our equilibrium and nonequilibrium simulations thus provide a self-constituent
picture of the long timescale conformational dynamics of the CoV-1 and CoV-2 spike proteins.
We note that our results are not conclusive with regards to the thermodynamics of activation and
inactivation. Instead, they provide a semi-quantitative picture of the kinetics. The propensity of
the active CoV-2 spike protein to maintain the “up” RBD conformation for a longer period of
time as compared to CoV-1 might explain why the CoV-2 has a better chance of remaining
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bound to ACE2 long enough to allow for the next step in the viral entry process, which in turn
could potentially be linked to the CoV-2’s comparatively high human-to-human transmissibility.

RESULTS
We have performed 5-µs-long unbiased all-atom MD simulations of both inactive and
active CoV-1 and CoV-2 spike proteins in explicit water. The active CoV-1 and CoVsimulations were repeated additionally twice for another 5 µs each (see Supporting Information MD Simulation details). We have also performed 80 independent nonequilibrium SMD
simulations of the CoV-1 and 2 spike proteins, each for 100 ns, to compare the activation and
inactivation of CoV-1 and CoV-2 spike proteins that are otherwise generally inaccessible to
unbiased MD. We have thus generated 40 µs of equilibrium and 8 µs of nonequilibrium
simulation trajectories in aggregate.
Within the timescale of our unbiased equilibrium simulations (i.e., 5 µs), the inactive
forms of both CoV-1 and CoV-2 spike proteins do not undergo any major conformational
transitions, with the RBDs remaining in the “down” position (Fig. 1A) [9, 38]. On the other
hand, a spontaneous large-scale conformational change occurs in the active CoV-1 spike protein
simulation (Fig. 1B), with the RBD moving from an active “up” position to a pseudo-inactive
“down” conformation that is different from the inactive conformation in the cryo-EM structure
[38]. This spontaneous conformational transition appears to occur due to interactions between
the NTD and RBD of the CoV-1 spike protein (Fig. 1B). Unlike the active CoV-1, the active
CoV-2 spike protein does not undergo any large-scale conformational transitions and remains in
the active state within the 5-µs simulations (Fig. 1B). Movie S1 in Supporting Information
demonstrates the differential behavior of CoV-1 and CoV-2 clearly.
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To examine the reproducibility of the above observations, the active CoV-1 and -2
simulations were repeated twice (see Supporting Information - MD Simulation details).
Consistent with Set 1, the active CoV-2 simulations do not show any significant conformational
change in Sets 2 and 3. The active CoV-1 simulations, on the other hand, undergo some
significant conformational change in Set 2 and Set 3; although these conformational changes are
not the same in the three different repeats. The dramatic change from the “up” to “down” (or
pseudo-inactive) conformation of the CoV-1 spike protein is only observed in Set 1; however, all
three sets show some significant conformational changes that are not observed in any of the
CoV-2 simulations. Root mean square deviation (RMSD) (Fig. S1) and root mean square
fluctuation (RMSF) (Fig. S2) analyses demonstrate the relative stability of the active CoV-2 as
compared to the active CoV-1 spike protein. A comparison of individual protomer RMSDs from
all 3 repeats of the active CoV-1 and CoV-2 spike protein trajectories, clearly shows that the
active CoV-1 spike protein is less stable overall as compared to the active CoV-2 (Fig. S1).
Similarly, RMSF analysis indicates that the RBD and NTD regions of the active CoV-1 spike
protein fluctuate more than the corresponding regions of the active CoV-2 (Fig. S2).
In order to quantify the spontaneous conformational transition that occurs in the active
CoV-1 spike protein, we measured the center-of-mass distance between the receptor-binding
motif (RBM) of protomer A and the S2 trimer of the spike protein (Fig. 1C). The RBM-S2
distance remains stable for both inactive states at ∼85 Å over 5 µs. For both the CoV-1 and
CoV-2 active states, the RBM-S2 distance is initially ∼100 Å but decreases to ∼85 Å for CoV-1
after 2 µs (Fig. 1C). This analysis clearly demonstrates that the final conformation adopted by
the RBD of the active CoV-1 spike is similar to the inactive state RBD conformations of both
CoV-1 and CoV-2, in terms of the RBM-S2 trimer distance (Figure 1C). On the other hand, the
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RBM-S2 trimer distance for the active CoV-2 spike protein remains relatively unchanged over 5
µs (Fig. 1C), consistent with the molecular images shown in Figs. 1A-B. Similarly, the angle
between the RBM of protomer A and the S2 trimer remains relatively unchanged for the CoV-2
active state, while the CoV-1 active simulation shows a behavior during the last 3 µs that is
similar to that of the inactive states of CoV-1 and CoV-2 (Fig. 1D).
The RBD-NTD contact analysis also demonstrates the RBD-NTD association in the socalled pseudo-inactive conformation observed in our CoV-1 simulations. We specifically
calculated the minimum distance between the RBD and NTD of protomer A for each system (Fig.
1E). While the RBM-S2 distance and angle calculations indicate that the behavior of the CoV-1
active state eventually resembles that of both inactive systems (Fig. 1C-D), the NTD-RBD
distance calculation showcases the unique behavior of the pseudo-inactive CoV-1 spike protein.
The NTD-RBD distance of the active protomer in CoV-1 fluctuates considerably over the first 2
µs of the trajectory, after which it decreases sharply to settle down around 2 Å (Figure 1E). This
clearly demonstrates that the RBD of the pseudo-inactive CoV-1 spike protein, that results from
the inactivation of the active CoV-1 spike, is in close proximity to the NTD as also shown in the
cartoon representations (Fig. 1B). This is not observed during any of the simulations of active
CoV-2 spike protein or either of the inactive spike proteins (Fig. 1A-B, 1E), thus indicating that
the pseudo-inactive conformation adopted by the initially active CoV-1 spike protein is unique.
The RBM hydration analysis provides more evidence that the pseudo-inactive CoV-1 is
truly inactive since its exposure to water (as a proxy to ACE2 accessibility) is quite similar to
that of inactive CoV-1 and 2 states. This is quantified using the estimated probability
distribution for the number of water molecules near the RBM during the last 500 ns of
simulations (Fig. 1F).
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FIG. 1. Unbiased simulations of the CoV-1 and CoV-2 spike proteins show a differential
dynamic behavior. (A-B) The initial and final MD snapshots of CoV-1 and CoV-2 spike
proteins starting from both inactive and active states. Protomer A in each protein is colored and
protomers B and C are shown in white. The RBD of the colored protomer has a distinctive color
from the rest of the protomer. Based on multiple repeats of these simulations, we have observed
that the active form of the CoV-2 spike protein is consistently more stable than the active CoV-1
spike protein. The active CoV-1 spike protein transitions spontaneously to a pseudo-inactive
conformation. (C) The center- of-mass distance between the S2 trimer of the spike protein and
the RBM of protomer A shown as a function of time. (D) The angle between the S2 trimer of the
spike protein and RBM of protomer A shown as a function of time. (E) Minimum distance
between the NTD and RBD of protomer A as a function of time for CoV-1 and CoV-2 spike
proteins in both active and inactive state simulations. (F) Probability density map of water within
5 Å of the RBM for the final 500 ns of simulation. In panels C-F, the same color code is used to
represent CoV-1-inactive (blue), CoV-1-active (magenta), CoV-2-inactive (red) and CoV-2active (orange).
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The water molecule count for the pseudo-inactive state (here, represented by the last 500 ns of
the simulation starting with the CoV-1 active state) is considerably lower than that of the CoV-2
active state and is comparable to the counts for the CoV-1/2 inactive states, further confirming
that the active CoV-1 spike protein undergoes a large-scale conformational transition and
becomes inactive (Fig. 1F).
While the measures discussed above provide clear evidence that the CoV-2 spike protein
behaves more as a stable structure in its active state as compared to CoV-1 spike protein, more
insight can be gained from more systematic analysis techniques such as principal component
analysis (PCA) [54] and dynamic network analysis (DNA) [55]. For instance, considering the
(PC1,PC2) space shows that the region sampled by the active protomer of the CoV-1 spike
protein is considerably larger than the region sampled by the corresponding protomers of the
CoV-2 spike protein (Fig. S3). Interestingly, the PCA analysis reveals that the most pronounced
conformational change (i.e., PC1) is related to the motion of the RBD towards the NTD in the
CoV-1 spike protein (Figure S3). For more PCA based analysis, see Supporting Discussion and
Figures S3-S5 in Supporting Information. Similarly, the DNA analysis provides more details on
the differential behavior of the spike proteins of CoV-1 and CoV-2. For instance, CoV-1
protomer A (i.e., the active protomer) shows several high inter-domain correlations (indicating
concerted motions), while these correlations are missing in the same protomer of CoV-2 (Fig.
S6). Similar trends were observed in all three Sets of CoV-1 and CoV-2 active state simulations
(Figs. S7-S10). Inter-protomer correlations also highlight the differential behavior of the active
CoV-1 and CoV-2 spike proteins (Fig. S11). For more DNA based analysis, see Supporting
Discussion and Figures S6-S11 in Supporting Information.
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FIG. 2. Unique salt-bridge interactions between the RBD and NTD of the active CoV-1 spike
protomer facilitate the transition to a pseudo-inactive conformation. (A-B) Time series of
D23/24-K365 (A/B) salt-bridge distances in CoV-1 spike protein simulations and (C-D) visual
representations of salt-bridge formation in the initially active CoV-1 protomer A. D23 and D24
(green) of the NTD form a salt-bridge with K365 (blue) of the RBD only in the pseudo-inactive
state of CoV-1. D23 and D24 are not present in the CoV-2 spike protein.
Our extensive electrostatic interaction analysis reveals that the driving force behind the
unique conformational transition observed in the initially active CoV-1 spike protein simulation
(Fig. 1) is at least partly a set of salt-bridge interactions that are unique to CoV-1. Residues D23
and D24 in the NTD interact with K365 in the RBD, forming stable salt bridges in the active
CoV-1 spike protein but not in the inactive state (Fig. 2). These fairly stable salt-bridges form
around the 1 µs mark (Fig. 2A,B), prior to the final movement of the RBD towards the NTD
(Fig. 1E). Residues D23 and D24 are not conserved in the SARS-CoV-2 spike protein.
Differential behavior is also observed for two sets of residues that are conserved in both CoV-1
and CoV-2 spike proteins (Fig.S12). R328 and D578 form a stable salt bridge in both active and
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inactive CoV-2 spike proteins while R315 and D564 do not form a salt-bridge in the CoV-1
spike proteins (Fig. S12A). Similarly, R273 and D290 form a stable salt bridge in both active and
inactive CoV-2 spike proteins while K258 and D277 do not form a salt-bridge in the CoV-1
spike proteins (Fig. S12B). Additionally, a conserved pair of residues form an intra-RBD
hydrogen bond in the active/inactive CoV-2 spike protein (Y396-E516) and the inactive CoV-1
spike protein (Y383-E502), but not in the active CoV-1 spike protein (Y383-E502) (Fig. S13).
These electrostatic interactions thus potentially contribute to the relative stability of the active
SARS-CoV-2 spike protein.
SMD simulations were performed to semi-quantitatively characterize the energetics of
the activation-inactivation process for the CoV-1 and 2 spike proteins. To induce the activation
or inactivation of individual protomers, we used the Cα RMSD of each protomer with respect to
a target structure (the inactive state for the inactivation process and the active state for the
activation process). 10 sets of 100 ns SMD simulations were performed for each system. The
conformational transition of an inactive RBD to the active “up” position was accompanied by a
decrease in the RBM-S2 angle and an increase in the RBM-S2 distance, as expected (Figure 3AB). Similarly, the inactivation of an active protomer was characterized by an increase in the RBMS2 angle and a decrease in the RBM-S2 distance, as expected (Fig. 3A-B).
Without performing strict free-energy calculations, we have used nonequilibrium work
measurements to compare the energetics of the CoV-1/CoV-2 spike protein activationinactivation process in a semi-quantitative manner. We have previously used similar methods to
investigate conformational transitions of other biomolecular systems [52, 53, 56, 57]. The
accumulated nonequilibrium work measured during the inactivation of an initially active CoV-2
protomer or the activation of an initially inactive CoV-2 protomer, is significantly larger than the
work measured during the inactivation or activation of the corresponding CoV-1 protomer (Fig.
3C-D). Similarly, the change in the associated Jarzynski average is also much higher for the CoV77

2 protomers (Fig. 3C-D, inset). We note that the Jarzynski average would only quantify the true
free energy if converged, which requires many more repeats. However, here we are only
interested inrelative behavior of the CoV-1 and CoV-2 in a qualitative or semi-quantitative manner
rather than accurately calculating any free energies [52, 56, 57]. These results suggest that the
CoV-2 spike protein has slower kinetics, due to higher barriers, in both directions. In other words,
the conformational changes associated with activation or inactivation of the spike protein
proceeds more slowly in CoV-2 relative to CoV-1. This is in good agreement with our observations
on the relative conformational stability of the active CoV-2 spike protein from the unbiased
simulations. The difference in the kinetics explains why we have been able to observe large-scale
conformational changes in some of the SARS-CoV-1 spike protein simulations but not in any of
the SARS-CoV-2 spike protein simulations. It is also important to note that the work analysis here
does not provide much information on the thermodynamics. To be able to make statements about
thermodynamics,we need to perform very accurate free energy calculations.
Our SMD simulations show that it is relatively difficult for the CoV-2 spike protein to
undergo a large-scale conformational transition between active and inactive states, when
compared to the CoV-1 spike protein. Although these SMD simulations were run using the full
trimers, they involved only a single protomer (protomer A) in the biasing schemes while the other
two protomers were not biased. These simulations were also repeated with all 3 protomers being
biased (Fig. S14), which verified the large difference between the CoV-1 and CoV-2 kinetics.
Our results indicate that the energy barriers associated with conformational changes that are
required for activation and inactivation are larger in the CoV-2 spike protein as compared to
CoV-1.
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FIG. 3. SMD simulations show that the CoV-2 spike protein has higher energy barriers
between active and inactive states as compared to the CoV-1 spike protein. (A) RBM-S2
angle between the beta sheet region of the RBM and the alpha helical region of S2, shown as a
function of time during SMD simulations. Protomer activation is characterized by a decrease in
the RBM-S2 angle. (B) RBM-S2 COM Distance between the beta sheet region of the RBM
and the alpha helical region of S2, as shown as a function of time during SMD simulations.
Protomer activation is characterized by an increase in the RBM-S2 distance.(C,D) Accumulated
non-equilibrium work as a function of time during SMD simulations for individual simulations.
Inset: The Jarzynski average over 10 individual work profiles shown in Panels C and D.
DISCUSSION

Using microsecond-level equilibrium and nonequilibrium MD simulations, we have
demonstrated that the active CoV-1 and CoV-2 spike proteins exhibit differential dynamic
behavior. The active CoV-2 spike protein remains relatively stable over 5 µs, whereas the active
CoV-1 spike protein undergoes conformational changes and adopts, at least in one simulation, a
pseudo-inactive conformation that is distinct from the well-characterized inactive “RBD-down”
conformation [38]. Our observation of a pseudo-inactive state of the CoV-1 spike protein
essentially agrees with the results of an experimental smFRET study that describes alternative
inactive states of the CoV-2 spike protein [48]. While this pseudo-inactive conformation is not
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observed in our CoV-2 spike protein simulations, it is certainly plausible that the CoV-2 spike
protein samples alternative conformational states during the spike protein activation process that
is dependent on the experimental/physiological conditions. In general, the key conclusion from
the observation of this pseudo-inactive state is that the published cryo-EM structures that are
produced under non-physiological conditions do not necessarily represent all relevant
conformational states of the spike protein.
While our unbiased simulations provide some insight into the spike protein inactivation
process, SMD simulations can access longer timescale conformational dynamics which allows
for a more detailed characterization of both activation and inactivation. An investigation of the
energetics of the activation-inactivation process using SMD simulations revealed that relative to
CoV-1, it is difficult for the CoV-2 spike protein to undergo a major conformational transition
from the active state to the inactive state or vice-versa. Nonequilibrium work measurements
indicate that large-scale conformational transitions occur relatively slowly in the CoV-2 spike
protein, which complements our observations on the relative conformational stability of the
active CoV-2 spike protein from the equilibrium simulations, explaining the spontaneous
conformational transition observed in the initially active CoV-1 equilibrium trajectory. The
results from our equilibrium and nonequilibrium simulations are thus very consistent and provide
extensive insights into the long-term dynamics of the CoV-1 and CoV-2 spike proteins. A recent
computational study has shown that the RBD of the CoV-2 spike protein has greater mechanical
stability than the RBD of the CoV-1 spike protein [58], which agrees with our observations on
the conformational stability of the active CoV-2 spike protein.
Several cryo-EM studies have reported differing results on the propensity of the CoV-1
and CoV-2 spike proteins to adopt certain conformations (eg. 1 RBD "up" or 3 RBDs "down").
For instance, Kirchdoerfer et al. state that the single RBD "up" conformation is highly favored
by the CoV-1 spike protein, with 58% of particles belonging to this population [41]. They did not
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observe the 3 RBDs "down" conformation [41]. On the other hand, Yuan et al. and Gui et al.
report that particles in the 3 RBDs "down" conformation make up approximately 56% and 27%
of the population respectively [38, 59]. Similarly, for the CoV-2 spike protein, Walls et al.
observe an approximately even split between the 1 RBD "up" and 3 RBDs "down"
conformations while Wrapp et al. only observe the 1 RBD "up" conformation [9, 27]. In our
study, we do not make any claims about the predominance or relative stability of these
conformations for the CoV-1 or CoV-2 spike protein. Instead, we focus exclusively on the
differential dynamic behavior of the CoV-1 active and CoV-2 active spike proteins. Our study
provides new insights into the kinetics, and not the thermodynamics, of the CoV-1 and CoV-2
spike protein activation process.
Using surface plasmon resonance and protein pull-down assays, Shang et al. have shown
that the CoV-2 spike RBD has significantly higher ACE2 binding affinity than the CoV-1 spike
RBD [60]. However, their results also indicate that the ACE2 binding affinity of the entire CoV2 spike protein is similar to or lower than that of the CoV-1 spike protein [60]. To explain this
“paradox”, the authors hypothesize that although the CoV-2 has a higher-affinity RBD as
compared to CoV-1, the CoV-1 favors the up state of the RBD more than the CoV-2 and thus has
a higher accessibility to ACE2. Since we do not make any claims regarding the thermodynamics
(i.e., up vs down stability), we can neither rule out nor provide evidence for this hypothesis based
on our simulations. However, given the fact that the spike-ACE2 binding is only the first step in
a cascade of events that result in S1-S2 cleavage and membrane fusion, it is important for the
spike-ACE2 association to last long enough so the rest of the process is triggered. Therefore,
kinetics is perhaps as important if not more important than thermodynamics here. Our hypothesis
based on the slower kinetics is that once the SARS-CoV-2 spike protein is activated, not only is
it ready to bind to ACE2 but it also favors staying bound for a long enough time such that a
cascade of events necessary for membrane fusion can occur.
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Unlike X-ray crystallography and cryo-EM, MD simulations facilitate the elucidation of
detailed hypotheses on the dynamic behavior of proteins and other biomolecules [46, 47].
However, each computational or experimental technique has its own assumptions and
limitations. Here, for instance, we chose to work with the non-glycosylated spike proteins of
CoV-1 and 2 to avoid complications when making comparisons. A recent study has shown that
glycosylation of the spike proteins might play an important role in the conformational dynamics
of the RBD [61, 62]. At this stage, we have not simulated the glycosylated spike proteins due to
the difficulty of modeling the correct glycan chains. It would be quite difficult to determine
whether conformational changes occur as a result of the intrinsic protein dynamics or the
differential glycosylation patterns of the CoV-1 and CoV-2 spike proteins imposed by our
modeling. However, we use the non-glycosylated form of the spike protein for both CoV-1 and
2, which makes the comparison justifiable.
Investigation of the "effective binding" process involving both receptor interaction and
spike protein activation will provide deeper insights into the enhanced infectivity of SARS-CoV2. Several studies have investigated RBD-ACE2 binding for both SARS CoV-1 [63–69] and
SARS-CoV-2 [9, 17, 27, 36, 37], while ignoring the conformational dynamics of spike protein
activation and inactivation. We propose that the “effective binding” process is different in the
CoV-1 and CoV-2 spike proteins, not only because of the variability of the RBD but also due to
the contribution of other regions, particularly the NTD, as seen in the CoV-1 pseudo-inactive
state, where the NTD interacts with RBD and therefore could block the ACE2 binding to RBD.
This is in qualitative agreement with the results of recent experimental and clinical studies which
highlight the importance of the spike protein NTD in the SARS-CoV-2 infection process [70–
75].
Several circulating SARS-CoV-2 variants with mutations or deletions in the NTD show
greatly reduced recognition by NTD-specific neutralizing monoclonal antibodies [70–75]. This
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strongly suggests that the NTD is under selective pressure from the host humoral immune
response [70–75]. Based on the observation of a previously unknown pseudo-inactive
conformational state for the spike protein, we hypothesize that the RBD-NTD interaction could
play a crucial role in the inactivation of the spike protein and that mutations in the spike NTD
could potentially have an effect on the transmissibility of the coronavirus. More generally, our
simulations suggest that the differential conformational dynamics associated with inactivation
and activation of the coronavirus spike protein might contribute to the increased transmissibility
of SARS-CoV-2 as compared to SARS-CoV-1 and some variants of SARS-CoV-2 as compared
to some other variants.
Several experiments could be performed in order to test the hypotheses presented in our
computational study. For instance, the importance of residues D23 and D24 from the CoV-1
spike NTD could be investigated via site-directed mutagenesis. This might provide some
additional insights on the conformational dynamics of the CoV-1 spike protein. Similarly, the
conserved residue pairs that exhibit differential behavior in terms of salt-bridge interactions
could be mutated in both spike proteins. Additionally, smFRET experiments could be used to
investigate a potential RBD-NTD interaction by measuring the distance between fluorophores
attached to each domain. Disulfide cross-linking experiments could also be used to investigate
residues in the NTD and RBD that potentially interact with each other.
As discussed previously, our study primarily sheds light on the conformational dynamics
of the SARS-CoV-1 and SARS-CoV-2 spike proteins. While differences in the dynamic
behavior of these spike proteins almost certainly contribute to differences in transmissibility and
infectivity, factors such as spike protein glycosylation and the behavior of other viral proteins
also need to be considered in order to provide a more complete hypothesis. Additional
experimental and computational studies are thus needed to fully investigate the differential
infectivity and transmissibility of SARS-CoV-1 and SARS-CoV-2.
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METHODS
Our simulations were based on cryo-EM structures of the SARS-CoV-2 spike protein in the
active (PDB entry:6VYB) [9] and inactive (PDB entry:6VXX) [9] states and the SARS-CoV-1
spike protein in the active (PDB entry:5X5B) [38] and inactive (PDB entry:5X58) [38] states.
The protein was solvated in a box of TIP3P waters with 0.15 M NaCl and was simulated using
CHARMM36m all-atom additive force field [76]. For details of our simulation and analysis
methods see Supporting Information.
DATA AVAILABILITY
Simulation and analysis scripts are available at https://github.com/bslgroup/Spike_Protein.
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CONCLUSION
Microsecond-level MD simulations have successfully been used to investigate
chemomechanical coupling in two very different proteins – hFGF1 and the CoV-1/CoV-2 spike
protein. Using a combination of microsecond-level unbiased MD simulations, SMD simulations,
restrained umbrella sampling simulations and a state-of-the-art binding affinity estimation
approach, the conformational dynamics of the heparin-hFGF1 complex has been characterized in
detail. For the first time, a destabilizing conformational transition was observed in the hFGF1
heparin-binding pocket in the absence of heparin. This provides an explanation for the
experimentally observed thermal instability of hFGF1. Unique intramolecular interactions
occurring within the heparin-binding pocket in the presence of heparin potentially play an
important role in stabilizing hFGF1. More research needs to be carried out to understand the
functional relevance of these interactions. The computationally determined binding affinity for
the heparin-hFGF1 interaction is in very good agreement with the binding affinity obtained from
ITC experiments. The results of the binding affinity study indicate that sampling along a proteinligand distance without restraints is less effective than sampling with restraints. Specifically, the
results show that restraining ligand orientation is key to arriving at a reasonable computational
binding affinity estimate.
Extensive equilibrium and nonequilibrium simulations were also used to investigate the
conformational dynamics of spike protein activation, which is an important part of the “effective
binding” process that leads to interaction with the human ACE2 receptor. The observation of a
previously unknown “pseudo-inactive” state of the CoV-1 spike protein, where the NTD
interacts with the RBD, suggests that the NTD could play an important role in spike inactivation
by blocking the RBD-ACE2 interaction. Recent experimental and clinical studies have shown
that CoV-2 variants with mutations in the NTD experience reduced recognition by NTD-specific
monoclonal antibodies, indicating that the NTD is under selective pressure from the host immune
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response1-6. This suggests that mutations in the NTD could potentially be linked to differential
transmissibility. This study also shows that the kinetics of the activation or inactivation process
are much slower for the CoV-2 spike protein compared to the CoV-1 spike protein, suggesting
that CoV-2 may potentially be more transmissible than CoV-1 as a consequence of spending
more time bound to the ACE2 receptor. Additional experimental and computational studies are
needed to further investigate these hypotheses.
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Figure S1. Cartoon representation of the dimeric hFGF1 X-ray crystal structure with
heparin hexasaccharide (PDB entry 2AXM) (related to Figures 1-4 and Table 1).
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Figure S2. Stability of heparin-bound hFGF1 assessed through RMSD and RMSF
calculations (related to Figure 1). (A) Internal RMSD time series for heparin-bound hFGF1
(Model2). (B) Internal RMSD time series for heparin-bound hFGF1 (Model1). (C) Internal
RMSD time series for the heparin-binding pocket of heparin-bound hFGF1 (Model2). (D)
Internal RMSD time series for the heparin-binding pocket of heparin-bound hFGF1 (Model1).
(E) RMSF estimation for heparin-bound hFGF1 (Model2). (F) RMSF estimation for heparinbound hFGF1 (Model1)
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Figure S3. Salt bridges associated with the conformational change in the apo model do not
form in the heparin-bound models (related to Figure 3). (A) Time series and cartoon
representation of the D84-K132 donor-acceptor salt bridge distance for heparin-bound Model 2.
(B) Time series of the D84-K132 donor-acceptor salt bridge distance for heparin-bound Model 1.
(C) Time series and cartoon representation of the D46-K127 donor-acceptor salt bridge distance
for heparin-bound Model 2. (D) Time series of the D46-K127 donor-acceptor salt bridge distance
for heparin-bound Model 1. (E) Time series of water molecule count within 3 Å of the heparinbinding pocket for heparin-bound Model 2. (F) Time series of water molecule count within 3 Å
of the heparin-binding pocket for heparin-bound Model 2.
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Figure S4. Table of intramolecular interactions unique to the heparin-binding pocket of
heparin-bound hFGF1 (Model 2) (Related to Figure 3E). Hydrogen-bonding occupancies are
similar in heparin-bound Model 1.
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Figure S5. The conformational change causes secondary structural changes in the apo
model (related to Figure 1 and Figure 3). (A) Cartoon representation of the secondary
structural change that occurs in the heparin-binding pocket of the apo model due to the
conformational change. (B) Secondary structure of the heparin-binding pocket of apo hFGF1 as
a function of simulation time. Parts of the heparin-binding pocket become unstructured after 2
microseconds. (C) Secondary structure of the heparin-binding pocket of heparin-bound hFGF1
(Model 1) as a function of simulation time. (D) Secondary structure of the heparin-binding
pocket of heparin-bound hFGF1 (Model 2) as a function of simulation time. The heparin-binding
pocket remains structured in both heparin-bound trajectories.
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Figure S6. Behavior of heparin hexasaccharide in the heparin-bound trajectories (related
to Figure 4 and Table 1). (A) The heparin hexasaccharide in Model 1 (blue) fluctuates
considerably before undergoing a 180° rotation. It settles into a more stable conformation after 2
μs. (B) The heparin hexasaccharide in Model 2 does not undergo any major positional changes.
Due to the differences in behavior of heparin in each model, slightly different intermolecular
interactions occur in terms of both occupancy as well as the residues involved.
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Figure S7. Time series of hFGF1-heparin intermolecular interactions (related to Figure 4
and Table 1). (A) Time series of hydrogen-bonding interactions between R136 and IDS4
(Model 1). (B) Time series of hydrogen-bonding interactions between R136 and IDS2 (Model 2).
(C) Time series of hydrogen-bonding interactions between K132 and SGN3 (Model 1). (D) Time
series of hydrogen-bonding interactions between K126 and SGN3 (Model 2)
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SIMULATION AND ANALYSIS DETAILS
MD Simulation Details
We have used all-atom equilibrium and nonequilibrium MD simulations to characterize the
conformational dynamics of the spike protein from SARS-CoV-2 and SARS-CoV-1. Our
simulations were based on cryo-EM structures of the SARS-CoV-2 spike protein in the active
(PDB entry:6VYB)1 and inactive (PDB entry:6VXX)1 states and the SARS-CoV-1 spike
protein in the active (PDB entry:5X5B)2 and inactive (PDB entry:5X58)2 states. Missing
residues for all 4 models were generated using Modeller.3 10,000 Monte Carlo iterations were
used to generate the initial models for the equilibrium simulations.3 CHARMM-GUI4,5 was
then used to build the simulation systems. Engineered residues were mutated back to the
wildtype and disulfide bonds were added to each model based on the information provided in
the respective PDB files.1,2 The protein was solvated in a box of TIP3P waters, and 0.15 M
NaCl (in addition to the counterions used to neutralize the protein) using CHARMM-GUI.4,5
All simulations were performed using the NAMD 2.136 simulation package with the
CHARMM36m all-atom additive force field7. The input files for energy minimization and
production were generated using CHARMM-GUI.4,5 Initially, we energy-minimized each
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system for 10,000 steps using the conjugate gradient algorithm.8 Then, we relaxed the
systems using restrained MD simulations in a stepwise manner using the standard
CHARMM-GUI protocol4,5 (”relaxation step”). In the next step, backbone and sidechain
restraints were used for 10 ns with a force constant of 1 kcal/mol.Å2 and 0.5 kcal/mol.Å2 ,
respectively (”restraining step”). The systems were then equilibrated with no bias for
another 10 ns (”equilibration step”). The initial relaxation was performed in an NVT
ensemble while the rest of the simulations were performed in an NPT ensemble.
Simulations were carried out using a 2-fs time step at 310 K using a Langevin integrator
with a damping coefficient of γ = 0.5 ps−1. The pressure was maintained at 1 atm using
the Nose-Hoover Langevin piston method.8,9 The smoothed cutoff distance for non-bonded
interactions was set at 10 to 12 Å and long-range electrostatic interactions were computed with
the particle mesh Ewald (PME) method.10
These initial simulations were executed on TACC Longhorn. The production run for
each model was then extended to 5 µs on Anton2,11 with a timestep of 2.5 fs. Conformations
were collected every 240 picoseconds. Initial processing of the Anton2 simulation trajectories
was carried out on Kollman. 11 Two additional 5 µs simulations were performed for both the
CoV-2 and CoV-1 active models on Anton2 (referred to as Set 2 and Set 3 in the manuscript).
As stated previously, cryo-EM structures (PDB entries:6VYB,5X5B)1,2 were used as starting
conformations for each model. In order to generate initial conformations for Set 2, the
original production run (”equilibration step” described previously) for each model was
extended by 0.5 ns on TACC Longhorn. The production runs were then extended again by
0.5 ns to generate the initial conformations for Set 3. 40 µs of simulation data was generated
in aggregate – 15 µs each for the active Cov-1/Cov-2 spike proteins and 5 µs each for the
inactive spike proteins.
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RBM-S2 Distance and Angle

To quantify the RBM-S2 distance, we defined centers of mass based on residues that form a
beta-sheet in the RBM region of each RBD (CoV-1: RBM residues 439 to 441, 479 to 481;
CoV-2: RBM residues 452 to 454, 492 to 494) and residues that encompass the S2 trimer
(CoV-1: S2 residues 672 to 1104; CoV-2: S2 residues 690 to 1147). We then measured the
vector distance between the two centers of mass and used the vector magnitude to quantify
the overall distance.
For the RBM-S2 angle, we chose residues at the top and bottom of the straightest region
of the S2 Trimer (alpha-helical regions in CoV-1: residues 970 and 1016; CoV-2: residues
914 and 987). Similarly, we also chose residues from the beta-sheet region of the RBM and
one at the bottom of the RBD (CoV-1: residues 348 and 478; CoV-2: residues 391 and 493).
We then defined a vector direction using the vector subtraction of the two chosen residues
in the S2 region and the residues of the RBD region, which were defined as v1 and v2. The
vector angle between the RBD and S2 was then calculated with the following equation:
arccos(

v1·v2

). The computed angle was subtracted from 180◦. An angle above ≈ 60◦

|v1||v2|

would indicate an RBD in the inactive conformation with respect to S2, and 0-40◦ would
indicate an RBD in the active conformation.

NTD-RBD Distance
To characterize conformational changes in the active and inactive states of both CoV-1
and CoV-2 spike proteins, we calculated the minimum distance between every residue of
the receptor-binding domain (RBD) and the N-terminal domain (NTD). We measured the
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distance between each residue pair in these regions (maximum distance cutoff was 20 Å) as
a function of time. The domains were defined as follows: CoV-2 RBD (residues 330 to 515);
CoV-2 NTD (residues 60 to 270); CoV-1 RBD (residues 330 to 550); CoV-1 NTD (residues
35 to 255).
RBM Hydration Analysis
The amount of solvent around the receptor-binding motif (RBM) was quantified using a
VMD 12 script. We calculated the number of water molecules within 5 Å of the RBM for
every frame of the last 500 ns of each trajectory and also plotted probability density maps
for each water count.
Principal Component Analysis (PCA)
PCA13 performed with ProDy14 was used to quantify the persistent conformational changes
and relative motions of the active and inactive states. Only the position of the C-α atoms
of the spike protein was considered when building the covariance matrix of atomic positions,
in order to focus on the large conformational changes and ignore side chain fluctuations.
Each trajectory was aligned with the positions from the cryo-EM structure before analysis
to remove translational motion of the protein from the variance calculations.
The CoV-1/CoV-2 active state (Set 1) and CoV-1/CoV-2 inactive state trajectories were
stripped down to trajectories of the individual protomers from each simulation. The
individual protomers were then analyzed together to compare and quantify the relative
motions of the active and inactive states. Through eigenvalue decomposition, the top twenty
principal components (PCs) were calculated for each protomer. The top two PCs for each
protomer have been plotted to identify the major motions of the protein.
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Dynamic Network Analysis (DNA)

DNA15 of the correlated motions of the protein provided further quantitative information on
the concerted motions of the C-α atoms of the protein. MD-TASK, 16 a software suite of MD
analysis tools, was used to calculate the correlation coefficient for the motion of each C-α
atom relative to the other C-α atoms. A correlation matrix M was generated for each of the
three protomers in all the simulated trajectories. Additionally, a correlation matrix for the
entire trimer was calculated for each simulation to explore correlations between structures of
different protomers. A step size of four frames was used during the correlation calculations to
reduce the processing times, given the large number of residues.
To quantify the differences in correlation between a protomer and some reference, a
difference matrix, ∆ was calculated,
∆ = |Mi  MRef. |,

(1)

where Mi is the correlation matrix of interest, and MRef is the correlation matrix of a
reference conformation. In this work, the difference between a protomer in an active
conformationand an inactive conformation was of interest. For this reason, the protomers in
the active simulations were compared with Protomer C in the inactive simulation, which
displayed relatively little motion.

Interaction Analysis
To identify interactions that contribute to the stability of the Cov-2 spike protein or play key
roles in the CoV-1 active conformational transition, we performed salt-bridge and hydrogenbond analysis for all SARS-CoV-2 and SARS-CoV-1 systems. Salt bridges were identified
using the VMD Timeline plugin 12 at a cutoff distance o f 4 . 0 Å. The salt-bridge cutoff
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distance is defined as the distance between the oxygen atom of the participating acidic residue
and the nitrogen atom of the basic residue. The VMD HBond plugin12 was used for hydrogen bond analysis. The donor-acceptor distance and angle cutoffs used were 3.5 Å and 3 0
degrees respectively. We report salt-bridge and hydrogen-bond interactions that illustrate
the differential behavior of the SARS-CoV-2 and CoV-1 spike proteins.

Steered Molecular Dynamics (SMD) analysis
To induce activation/inactivation of a protomer initially in the inactive/active
conformation, we defined collective variables based on the Cα RMSD of each protomer in the
CoV-1 and CoV-2 systems. Reference coordinates were taken from the corresponding
active/inactive structure for both CoV-1 and CoV-2 protomers. The atoms chosen were
based on the total number of modeled residues in the CoV-2 structures. Structural analysis
of CoV-1 and CoV-2 was employed to ensure that equivalent Cα atoms were steered in all
simulation sets. 1037 atoms were steered for any given protomer and the following
residue range was used: 27 to 239, 244 to 315, 322 to 662, 673 to 809, and 831 to 1104.
These atoms span the entire protomer, starting from the NTD and ending approximately
at the C-terminus of the S2 region. A force constant of 250 kcal/mol/Å2 was used for SMD
simulations involving a single protomer and a force constant of 750 kcal/mol/Å2 was used
for SMD simulations involving all three protomers. The systems used for each simulation
were taken from the outcome of the ”equilibration step” as explained above. Utilizing the
multi-copy capabilities of NAMD, we performed 10 sets of 100 ns RMSD steering for each
system – 8 µs of simulation time in aggregate.
For all SMD time series analyses, each data point was averaged for the 10 sets and
standard deviation was calculated. Each analysis was plotted with 100 points and error bars
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were derived from the standard deviation. The RBM-S2 distance and angle calculations were
performed as described previously. Using the Jarzynski relation 17 we calculate the Jarzynski
average at time t during the activation or inactivation process as:

where kB and T are the Boltzmann constant and the temperature, respectively and Wi(t) is
the work accumulated from the beginning of the SMD simulation i up to time t. The above
average would converge to the free energy for large number of trajectories (N → ∞). For
N = 10, the above average simply provides a semi-quantitative measure for relative energetic
comparisons. 18–21

Supporting Discussion : Principal Component Analysis and Dynamic Network Analysis

We performed principal component analysis (PCA) to validate our claim that the active
form of the CoV-2 spike protein is more stable than the active CoV-1 spike protein and
to provide insight into the mechanistic aspects of the spike protein activation-inactivation
process. When the individual protomer trajectories (see Methods section) from the CoV1/CoV-2 active (Set 1) and inactive simulations are projected onto the space of their first
two principal components (PC1 and PC2), it clearly demonstrates that the CoV-1 active
protomer A samples a much larger region in the PC1 space than CoV-2 active protomer A
(Figures S3A, S3C). This is further evidence of the relative stability of the active CoV-2
spike protein in comparison to the active CoV-1 spike protein.
A visual representation of PC1 for all protomers from the CoV-1 spike protein
simulations shows that the RBD undergoes the most pronounced motions directed inward
towards the NTD (Figure S3B). On the other hand, a visual representation of PC1 for the
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CoV-2 spike protein shows that the RBD and NTD tend to move away from each other
slightly and that the fluctuations are significantly smaller than in the CoV-1 spike protein
(Figure S3D). The most pronounced collective motion in each system (PC1) describes the
distinct motions associated with the RBD, that play key roles in the inactivation of the active
CoV-1 spike protein and maintenance of the active conformation of the CoV-2 spike protein
(Figure 1). This highlights the differential dynamic behavior of the active CoV-1 spike
protein.
PC2 describes the relative motions of the NTD and RBD, showing that the NTD
motion is more pronounced in CoV-1 (Figure S4). The motions associated with PC2 are
roughly the opposite of those associated with PC1 in terms of direction. PC2 also shows that
the CoV-1 spike protein has more regions outside the NTD and RBD that show high
variance (Figure S4). Similar trends are observed in Sets 2 and 3 of the active state
simulations (Figure S5). While different protomers are involved, the active CoV-1 spike
protein still undergoes more pronounced motions in both PC1 and PC2 compared to the
active CoV-2 spike protein (Figure S5). These observations are in agreement with our claim
that the active CoV-2 spike protein is relatively stable and that the active CoV-1 spike
protein transitions spontaneously to a pseudo-inactive conformation.
The inferences drawn from PCA are also supported by dynamic network analysis
(DNA). Differential behavior of the active CoV-1 and CoV-2 spike proteins manifests in the
correlation of motions between the various domains in individual protomers. In Figure S6A,
correlation heat maps of active CoV-1 protomer A (Set 1) and inactive CoV-1 protomer C are
presented, along with the difference between the active state and the reference structure
(inactive protomer C). The heat map for active Cov-1 protomer A shows regions of high
correlation and anticorrelation between several domains of the protomer. The NTD correlates
strongly with itself while anticorrelating with the RBD and parts of the S2 region. The
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reference protomer, inactive CoV-1 protomer C, shows a general reduction in correlation
across all regions (Figure S6A). The NTD does correlate with itself, but not as strongly as
in the active CoV-1 protomer A.
Similarly, the NTD-RBD anticorrelations were reduced. The ∆ matrix of differences
between active CoV-1 protomer A and inactive protomer C identified the regions where the
correlations were most different. Correlations between S1-C and the NTD/RBD changed
significantly, as did correlations between the RBD and S2 region (Figure S6A).
The correlations and anti-correlations observed for active CoV-2 protomer A (Set
1) were not as strong as those observed for active CoV-1 protomer A (Figure S6B). Similar
to CoV-1, anti-correlation occurs between the NTD and RBD but is not as pronounced.
Very low correlation was observed between the NTD and S1-C/S2 regions, also
differentiating CoV-2 from CoV-1. The active CoV-2 protomer A is closer to the stable
inactive CoV-2 protomer C, as shown in the ∆ matrix (Figure S6B). DNA correlation heat
maps for all protomers in Set 1 of the CoV-1/CoV-2 active state simulations are shown in
Figures S7 and S8 respectively. Similar trends were observed in Set 2 and Set 3 of the
CoV-1 and CoV-2 active state simulations (Figure S9-S10). These observations thus
provide further evidence of the relative stability of the active CoV-2 spike protein.
The concerted movements of each protomer relative to the rest of the trimer also
highlight the differences between the active CoV-1 and CoV-2 spike proteins. Heat maps
showing correlations between NTD regions of different protomers are presented in Figure
S11A. Stronger correlations and anticorrelations occurred in Sets 2 and 3 of the active CoV1 simulations (Figure S11A). Set 2 showed moderately strong anticorrelations between
NTDs A-C and NTDs B-C. Stronger anti-correlations between NTDs A-B and NTDs B-C
occurred in Set 3, with moderate correlations between NTDs A-C. The active CoV-2
simulations showed similar correlations across all three simulation sets, with slightly
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increased values in Set 3 (Figure S11A). These observations are consistent with a more
stable conformation for the active CoV-2 spike protein.
Figure S11B shows a similar trend with correlations between the NTD and RBD
regions of different protomers. Sets 2 and 3 of the active CoV-1 spike protein trajectories
showed stronger correlations between the NTD and RBD regions than the corresponding
CoV-2 trajectories (Figure S11B). In particular, RBD C of Sets 2 and 3 had strong
correlations or anticorrelations with the NTDs of all protomers (Figure S11B). The CoV-2
simulations displayed lower correlations for all the NTD-RBD combinations, with similar
results for both active state and inactive state trajectories (Figure S11B). This recapitulates
our other observations of greater conformational stability of the active CoV-2 spike protein
relative to the active CoV-1 spike protein (Figures 1, S3, S6).
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Figure S1: C-α RMSD for individual protomers. The C-α RMSD calculated for each
protomer relative to the initial cryo-EM structure over the 5 µs simulation is plotted for the
inactive spike simulations and three sets of active spike simulations. Protomer A is colored
dark grey, protomer B is colored light blue, and protomer C is colored dark red. The active
CoV-2 spike protein is more stable overall than the active CoV-1 spike protein.
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Figure S2: C-α RMSF for individual protomers. The C-α RMSF for each protomer
relative to the initial cryo-EM structure position was calculated for the inactive spike
simulations and three sets of active spike simulations. Protomer A is colored dark grey,
protomer B is colored light blue, and protomer C is colored dark red. The NTD and RBD of
the active CoV-1 spike are more flexible than the corresponding regions of the active CoV-2
spike.
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Figure S3: Principal component analysis demonstrates that the active CoV-2 spike
protein is more stable than the active Cov-1 spike protein. (A) Scatter plot of PC1
and PC2 for each protomer in the active and inactive CoV-1 simulations. Protomers from
inactive state simulations are colored red while protomers from active state simulations are
colored magenta. Lighter/darker colors represent earlier/later stages in the simulation.
(B) Visual representation of PC1 with the blue arrows at each C-α atom indicating
direction and magnitude of variance. The RBD of the CoV-1 spike protein shows
pronounced motions in the direction of the NTD. (C) Scatter plot of PC1 and PC2
for each protomer in the inactive and active CoV-2 simulations. Protomers from inactive
state simulations are colored green while protomers from active state simulations are
colored yellow. The active CoV-2 spike protein is relatively stable and samples
significantly fewer conformations in the PC1 space in comparison to the active Cov-1
spike protein. (D) Visual representation of PC1 with the cyan arrows at each C-α atom
indicating direction and magnitude of variance. The NTD and RBD of the CoV-2 spike
protein show slight movement away from each other.
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Figure S4: Visual representation of PC2 for all protomers in the inactive and active
(Set 1) spike simulations for CoV-1 and CoV-2. (A) Visual representation of PC2 for
all CoV-1 protomers with the blue arrows at each C-α atom indicating direction and
magnitude of variance. (B) Visual representation of PC2 for all CoV-2 protomers with the
blue arrows at each C-α atom indicating direction and magnitude of variance. The NTD
motions contribute more to the conformations sampled in the PC2 space than the PC1
space. These NTD motions are more pronounced in the CoV-1 spike, which also has
more regions outside the NTD/RBD that show high variance.
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Figure S5: PCA of all protomers in the inactive and active (Sets 2 and 3)
simulations for CoV-1 and CoV-2. (A) Scatter plot of PC1 and PC2 for Set 2 of CoV-1
and CoV-2 active and inactive spike simulations. (B) Scatter plot of PC1 and PC2 for Set
3 of CoV-1 and CoV-2 active and inactive spike simulations. The coloring is the same as
seen in Figure 3 with darker shades representing frames towards the end of the
simulations. The active CoV-2 spike clearly samples fewer conformations in both PC1
and PC2 spaces than the active CoV-1 spike.
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Figure S6: Dynamic network analysis shows that intra-protomer correlations
and anticorrelations are relatively strong in the active CoV-1 spike protein
simulations. (A) DNA heat maps showing the correlation of motions for the active
CoV-1 protomer A, inactive protomer C (reference), and the difference matrix. (B)
DNA heat maps showing the correlation of motions for the active CoV-2 protomer A,
inactive protomer C (reference), and the difference matrix. Correlations are shown in
purple and anti-correlations are shown in orange, with the darker colors indicating
greater correlation/anti-correlation. Colored labels for the NTD (green), RBD (red),
RBM (yellow), S1-C (cyan), and S2 (magenta) regions are positioned over the
appropriate residues. The delta matrix identifies differences in protomer correlation
between the active and reference inactive protomer. A theoretical maximum for ∆ is 2,
but the observed maximum was less than 1.3. Differences in correlation are shown as
a purple gradient with darker purple indicating larger difference.
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Figure S7: DNA correlation heat maps and ∆ matrix for all protomers from the
CoV-1 inactive and CoV-1 active (Set 1) spike simulations. DNA heat maps
showing the correlation of motions for the CoV-1 inactive protomers (first row), the
CoV-1 active protomers from Set 1 (second row) and the difference matrices. The
inactive protomer C correlation matrix, indicated by the dotted box, is the reference
used for calculating the ∆ matrix.
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Figure S8: DNA correlation heat maps and ∆ matrix for all protomers from the
CoV-2 inactive and CoV-2 active (Set 1) spike simulations. DNA heat maps
showing the correlation of motions for the CoV-2 inactive protomers (first row), the
CoV-2 active protomers from Set 1 (second row) and the difference matrices. The inactive
protomer C correlation matrix, indicated by the dotted box, is the reference used for
calculating the ∆ matrix.
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Figure S9: DNA correlation heat maps and ∆ matrix for all protomers from
Set 2 of the CoV-1 and CoV-2 active spike simulations. (A) DNA heat maps
showing the correlation of motions for the CoV-1 active (Set 2) protomers (first row)
and the difference matrices (second row). The reference matrix from Figure S7 was
used for ∆ matrix calculations. (B) DNA heat maps showing the correlation of motions
for the CoV-2 active (Set 2) protomers (third row) and the difference matrices (fourth
row). The reference matrix from Figure S8 was used for ∆ matrix calculations.
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Figure S10: DNA correlation heat maps and ∆ matrix for all protomers from
Set 3 of the CoV-1 and CoV-2 active spike simulations. (A) DNA heat maps
showing the correlation of motions for the CoV-1 active (Set 3) protomers (first row)
and the difference matrices (second row). The reference matrix from Figure S7 was
used for ∆ matrix calculations. (B) DNA heat maps showing the correlation of
motions for the CoV-2 active (Set 3) protomers (third row) and the difference
matrices (fourth row). The reference matrix from Figure S8 was used for ∆ matrix
calculations.
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Figure S11: Dynamic network analysis shows that inter-protomer correlations and
anticorrelations are relatively strong in the active CoV-1 spike protein
simulations. (A) DNA heat maps showing the correlation of motion between the NTD
regions of different protomers. (B) DNA heat maps showing the correlation of motion
between the NTD and RBD regions of different protomers. Correlations are shown in
purple and anti-correlations are shown in orange, with the darker colors indicating
greater correlation/anti-correlation.

121

Figure S12: Conserved residues show distinct differential behavior in the CoV-1
and CoV-2 spike proteins. Time series and visual representation of the minimum saltbridge distance for (A) R315/328 (blue) - D564/578 (green) and (B) K258/R273 (blue)
- D277/290 (green), shows that salt-bridges are formed in the CoV-2 spike protein but
are absent in the CoV-1 spike protein. These salt-bridges potentially contribute to the
higher relative stability of the CoV-2 spike protein. CoV-1 inactive is colored red,
CoV-1 active is colored magenta, CoV-2 inactive is colored olive-green and CoV-2
active is colored orange.
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Figure S13: Hydrogen bond analysis for a conserved residue pair within the
RBD. (A) Time series and visual representation of the minimum H-bond donoracceptor distance between Y383/396 (blue) and E502/516 (green), in the CoV-1 and CoV2 spike respectively. CoV-1 inactive is colored red, CoV-1 active is colored magenta,
CoV-2 inactive is colored olive green and CoV-2 active is colored orange. Table (B)
shows the occupancy (%) of the salt-bridge and hydrogen-bond interactions between
conserved residue pairs, for all protomers from all simulation sets.
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Figure S14: Three protomer SMD simulations. (A) RBM-S2 Angle between the
beta sheet region of the RBM and the alpha helical region of S2, shown as a function of
time. Protomer activation is characterized by a decrease in the RBM-S2 angle. (B) RBMS2 COM Distance between the beta sheet region of the RBM and the alpha helical region
of S2, shown as shown as a function of time. Protomer activation is characterized by an
increase in the RBM-S2 distance.(C,D) Accumulated non-equilibrium work as a function
of simulation time. Inset: Jarzynski average of non-equilibrium work.
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